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Cystic Fibrosis (CF), affecting 1 in 3,500 live births in the US, is a disease caused 
by aberrant expression of the Cystic Fibrosis Transmemebrane Conductance Regulator 
(CFTR).  While a multi-organ disease, CF-related complications and degradation of the 
lung is the leading cause of mortality. There are treatments to combat treatments but none 
that are curative. Recent advances in reprogramming and the ability to genetically modify 
the resulting induced pluripotent stem cells (iPSCs) have provided an alternative to 
conventional gene therapies thus far attempted for CF. Here we describe the in vitro 
generation of iPSCs starting from fibroblast cells obtained from a CF patient. These cells, 
like embryonic stem cells, show evidence of the ability to differentiate into any cell type. 
Then, using zinc finger nucleases (ZFNs) to induce a double strand break at the CF loci, 
we facilitated homologous directed repair of the break by providing a donor molecule 
that would, upon recombination, correct the disease-conferring mutation. In doing so, we 
observed an unpredicted allele-specific recombination, which could be applicable for 
gene correction of other diseases like those caused by dominant negative mutations. We 
interrogated the original CF fibroblast cells, the CF-iPSCs, and corrected iPSCs by whole 
genome and exome sequencing to evaluate genomic integrity after reprogramming and 
correction. Furthermore, in vitro differentiation of corrected iPSCs towards lung and 
thyroid lineages produces cells that express the mature CFTR protein isoform. This is the 
first report of site-specific correction of the CFTR gene in CF-specific iPSCs. 
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1.1 Cystic Fibrosis 
Cystic Fibrosis (CF) is the most common autosomal recessive disease among 
Caucasian populations, with an incidence of about 1 in 3,500 (1) CF is a monogenic 
disorder with CF carriers showing no clinical symptomology. The CF gene is located on 
chromosome 7 and encodes a 1480 amino acid protein, Cystic Fibrosis Transmembrane 
Conductance Regulator (CFTR). CF is caused by any of more than 1000 mutations (2) in 
the CFTR gene that fall into 6 classes resulting in either: I) no CFTR synthesis, II) 
defective processing, III) misregulation, IV) altered conductance, V) partly defective 
production or processing, or VI) defective regulation of other channels (3). The most 
prominent mutation, ∆F508, is a class II mutation. The ∆F508 mutation is a deletion of 
three nucleotides resulting in a deletion of phenylalanine at amino acid position 508 and 
occurs in ~70% CF alleles (4). Another severe mutation is ∆I507, which is prominent in a 
population in north west France (5); compound heterozygotes with genotype 
∆I507/∆F508 have also been documented (6, 7). 
As a member of the ATP binding cassette transporter family, the CFTR protein 
has a regulatory domain, two nucleotide-binding domains, and two membrane-spanning 
domains (8, 9). Upon reaching conformational maturation during normal protein 
production, the wild-type (wt) CFTR protein is coated with COPII in the endoplasmic 
reticulum (ER), which leads to budding from the ER and transport to the Golgi for further 
processing (3). The ∆F508 CFTR protein, although synthesized, fails to fold correctly 
and does not achieve the mature, glycosylated form. Maturation of the wild-type protein 
has proven to be inefficient; even more so for the ∆F508 protein. Approximately 75% of 
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wt protein and 100% of ∆F508 protein do not reach structural maturity and are degraded 
in the ER by the ubiquination-proteasome system (10). 
1.1.1 CF pathophysiology 
CFTR is normally expressed on the apical surface of various epithelial tissues, 
including the lung, sweat glands, intestine, pancreas, and reproductive organs (4, 9, 11-
13). Though a complex disease affecting many organs, CF-associated lung disease is the 
major cause of morbidity and mortality (14). In the lung, CFTR functions as a cAMP-
activated chloride channel. The prevailing hypothesis of how the ∆F508 mutation results 
in the pathophysiology of CF is that the absence of mature CFTR protein results in 
aberrant chloride transport and epithelial sodium channel (ENaC) upregulation, causing 
increased sodium and water reabsorption (2, 4, 15). Resulting dehydration of the air 
surface liquid (ASL) and thickening of the mucous covering the lung epithelium leads to 
impaired mucous clearance, thereby creating a microenvironment in which bacteria thrive. 
Patients thus suffer from recurring bacterial infections and chronic inflammation, which 
eventually leads to respiratory failure and death. Other CF symptoms include 
malabsorption in the intestine, pancreatic insufficiency, and increased chloride and 
sodium levels in the sweat (which is used often to diagnose CF). Furthermore, 91-98% of 
CF males are sterile due to defective or absent vasa deferentia (16).  
1.1.2 Treatments 
Current treatments for CF act primarily to ameliorate and manage symptoms of 
the disease. CF patients, for example, maintain a strict and rigorous regimen of nutrition 
to overcome malnutrition resulting from abdominal obstruction; chest physiotherapy to 
loosen the mucous and facilitate clearance; antibiotic treatment upon bacterial infection; 
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and inhaled steroids or non-steroidal drugs to fight inflammation (2, 3, 17). As a result of 
improvements in these treatments, the median survival rate of CF patients has increased 
to 35 and 40 years; by comparison, in the 1970s CF patients were not expected to survive 
beyond adolescence (18). Nonetheless, the quality of life for CF patients remains 
dampened due to the rise of drug-resistant bacteria and disease related complications in 
other organs (such as liver disease, diabetes, and fertility issues) (19). Comprehensive 
treatment of CF would have to address the disease in these other tissues, as well as 
provide more curative (rather than symptomatic) approaches for lung disease. 
To get at the underlying issue (i.e. aberrant CFTR protein expression at the cell 
surface), there are a number of studies focused on chemical chaperones and small 
molecules that rescue ∆F508 CFTR trafficking, such as glycerol, genestin and 
benzoquinolizinium compounds (10, 20-22). However, it has been shown that, though the 
∆F508 CFTR protein can be facilitated to reach the apical surface, the mutant protein has 
a decreased half-life (10). Furthermore, evidence that processing of ∆F508 CFTR is 
tissue dependent, with differences even within the lung, suggests that bypassing ER 
quality control and trafficking alone may be insufficient for treatment of CF (23). 
 Since the CFTR gene was discovered in 1989 (4), gene therapy has been 
considered as a potential therapeutic approach to curing CF. There have been attempts to 
deliver the CF gene by lentivirus (24, 25), adenovirus (26-28) and adeno-associated virus 
(29, 30). However, several barriers – both immune and mechanical – have prevented 
these attempts from being clinically beneficial. In the normal lung airway, for example, 
natural defenses against pathogens (i.e. mucous and mucociliary clearance) also serve as 
effective barriers to delivery of gene therapy reagents. This is exacerbated in a CF lung 
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where decreased ASL and thickened mucous create a barrier that is more impervious. 
Also, chronic bacterial infection leads to increased numbers of neutrophils, which also 
serve as a hindrance to viral delivery of gene therapies (27, 31). Another complication is 
that most viral receptors are localized basolaterally (32, 33). Though this can be 
circumvented by using agents like EGTA to transiently disrupt tight-junctions and, 
thereby, make the receptors accessible (28, 34), doing so could worsen infection and 
increase the risk of systemic bacterial infection (1). Furthermore, in clinical trials in 
which delivery the CF gene to patients was accomplished by either adenovirus (26) or 
adeno-associated virus (35), there has been evidence of cellular and humoral adaptive 
immune responses against repeated administration with no increase in gene transfer. 
In addition to overcoming these barriers, a critical consideration is the degree to 
which CFTR expression needs to be restored (i.e. percentage of cells expressing) for 
successful gene therapy of CF. In initial studies of mixed populations of a CF airway cell 
line and retrovirally-corrected airway cell line, epithelial cultures consisting of 6-10% of 
corrected cells was sufficient to restore chloride transport to levels of 100% of corrected 
cells (36). However, to restore ENaC activity to normal levels, more than 90% of cells 
required CFTR overexpression (37). One drawback of these studies is that they were 
performed in airway cell lines, which may not replicate in vivo epithelium. To overcome 
this hurdle, Farmen et al. used mixtures of freshly isolated wild-type and CF airway cells 
at varying proportion and found that a 20% wild-type and 80% CF mixture generated 
70% of the Cl- current that 100% wild-type epithelium did, indicating that even a 20% 
correction would be clinical beneficial (10). While the percent of cells that need to be 
corrected are still low, there is some concern that “supercorrection” of CFTR in these 
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cells may lead to mislocation of CFTR to the basolateral membrane, though this too has 
been refuted (10, 38). 
1.1.3 Cellular expression of CFTR 
Because CF morbidity and mortality is primarily associated with lung failure, 
characterization of CFTR expression within the lung has been explored extensively. The 
respiratory system is a complex branching organ consisting of proximal and distal parts. 
The proximal part of the lung includes all the major conducting airways: the nose, trachea, 
and bronchi. These structures are lined with a psuedostratified columnar epithelium 
consisting of ciliated and non-ciliated cells, basal cells, goblet cells and submucosal 
glands (FIGURE 1.1). The distal airway includes the bronchioles and alveoli, in which 
gas exchange occurs. A simple ciliated epithelium with Clara cells, submucosal glands, 
and a few goblet cells line the bronchioles. As one moves distally, the ratio of Clara cells 
to ciliated cells increases. Finally, the epithelial lining the alveoli consists only of two 
cells types, alveolar type I and II cells.  
Unfortunately, characterization of CFTR in the respiratory cells/tissue has resulted in 
contradictory findings. In early studies, Engelhardt and collegues made compelling 
arguments for the submucosal glands as the predominant site of CFTR expression (39). 
They also detected CFTR mRNA by in situ hybridization and protein by 
immunofluorescence in non-ciliated cells of the bronchioles and alveoli (40). However, 
several more recent studies have localized CFTR expression to the ciliated cells, not the 
submucosal glands (13, 41). These contradictions are probably due to experimental 
complications, including issues with antibody sensitivity as some antibodies have 
inaccessible epitopes after routine tissue preservation. Most recently, Kreda et al. 
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FIGURE 1.1 Lung structure and cell populations. Though there are cellular 
differences between murine and human airways, most studies on adult lung, particularly 
those attempting to identify lung stem cells, have used mouse models. The human lung 
consists of proximal (trachea and bronchi) and distal (bronchioles and alveoli) branches 
of differing epithelial organization to suit function. The proximal trachea and bronchi are 
composed of a pseudo-stratified epithelium of ciliated and non-ciliated cells. There is 
evidence for two populations of progenitor stem cells (denoted with an asterisk) in the 
trachea and bronchi: basal cells and serous cells within the submucosal glands. In the 
bronchioles, the basal cells are replaced by Clara cells, which are the putative progenitor 
cell population for this region. The epithelium in the alveoli is much simpler with just 
alveolar type I and type II cells, the latter believed to have progenitor capacities. In 
addition to decreased complexity of epithelial organization as one moves distally towards 
the alveoli, CFTR expression is evidenced to decrease as well. 
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reported in situ hybridization of CFTR mRNA and immunolocalization of CFTR protein 
in nasal and bronchial airways was greater in the superficial epithelium than the 
submucosal glands (42). Here, laser confocal microscopy was used to detect 
immunostaining by anti-CFTR antibodies reported to have 10-100 higher sensitivity than 
those used previously (43). 
1.2 Induced Pluripotent Stem Cells  
Induction of pluripotency (the ability to differentiate into all three germ layers) in 
somatic cells by defined factors in vitro holds great promise for the field of regenerative 
medicine as well as for disease modeling and drug testing (FIGURE 1.2). The appeal of 
these induced pluripotent stem cells (iPSCs) for regenerative medicine is 1) the potential 
for transplantation of not only terminally differentiated cells but also stem progenitors 
and 2) that these transplanted cells are autologous, having been derived from the patient’s 
own cells. iPSCs may provide both short- and long-term cellular therapy with little to no 
risk of immune rejection based on histo-incompatibility. 
1.2.1 Generation of iPSCs 
When reprogramming was first reported in 2006 by Takahashi et al., pluripotency 
was induced in murine fibroblast cells by ectopic expression of four transcription factors: 
Oct4, Sox2, Klf4, and c-Myc (44). By 2007, two independent groups quickly reproduced 
this by reprogramming human fibroblast cells (45, 46) and, since then, iPSCs have been 
generated from several tissues including keratinocytes (47), pancreatic beta cells (48), 
and B lymphocytes (49). Furthermore, a myriad of disease-specific iPSCs have been 
generated, including Cystic Fibrosis (50-53). 
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FIGURE 1.2 Potential applications for induced pluripotent stem cells (iPSCs). 
Somatic cells like skin fibroblasts, which can be easily obtained, can be reprogrammed to 
induce an embryonic-like pluripotent state by ectopic expression of a defined set of 
factors. These iPSCs can be used for disease modeling either by reprogramming disease-
specific cells or by introducing disease conferring mutations; followed by differentiation 
to regenerate somatic cells used for drug screening and toxicity testing; and autologous 
(patient-specific) cellular therapy.  
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Ectopic expression of the reprogramming factors was first achieved by retroviral 
transduction. This presented several barriers for clinical use of such cells. For example, 
though one of the hallmarks of a fully reprogrammed cell is that the transgenes are 
silenced and the endogenous pluripotential network genes reactivated (54-56), Okita et al. 
found that 20% of the adult chimeras generated from iPSCs formed tumors due to 
reactivation of c-myc, a known oncogene (57). This has led to reprogramming without c-
Myc; although such 3 factor reprogramming is of lower efficiency (58). While 3 factor 
reprogramming efficiency can be improved by treatment of somatic cells with valproic 
acid (59), integration of exogenous reprogramming factor cDNAs –  c-Myc included or 
not – still raises concerns of insertional mutagenesis as it has been demonstrated that 
reprogrammed cells can have anywhere from 10 to 20 proviral integrations (45, 54, 60). 
Several groups have now demonstrated the ability to reprogram human cells using a 
variety of methods that reduce or eliminate the risk of insertional mutagenesis, including 
the use of excisable polycistronic lentiviral vectors (61-63), non-integrating Sendai virus 
(64),  piggyBac transposon (65), nonintegrating episomal vectors (66), and recombinant 
proteins (67). Interestingly, Somers et al. demonstrated that, using an excisable 
polycistronic lentiviral system, they were able to reprogram cells with only one 
integration of the vector (63).  
1.2.2 Relationship between iPS and embryonic stem cells  
Like embryonic stem cells (ESCs), iPSCs express key stem cell markers and 
demonstrate the ability to form teratomas containing cell types of all three germ layers, 
evidence of a pluripotent state. In the case of mouse iPSCs, they can be used to derive 
chimeric mice (49, 58). It has also been demonstrated that these iPSCs have global 
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patterns of histone methylation similar to ESCs and reprogramming of female somatic 
cells reactivates the inactive X-chromosome (54).  
Though highly similar to ESCs, several reports have indicated that iPSCs may be 
distinguishable from ESCs. For example, using high resolution SNP to analyze primary 
human fibroblast line and various passages of the iPSC clones generated from that line, a 
higher number of copy number variations (CNVs) was found compared to non-
pluripotent cells (68). Laurent et al. found the reprogramming process associated with 
deletions in tumor suppressor genes, some of which were selected against with long-term 
passaging. Hussein et al. likewise found that some CNVs arising de novo in early passage 
iPSCs have a selective disadvantage with further passaging, driving the lines towards a 
genetic state resembling that of ESCs (69). There is also evidence of selection for 
chromosomal aberrations in both ESCs and iPSCs over prolonged culture (70-72) and 
that iPSCs have additional abnormalities as a result of the reprogramming process itself 
(73). 
At this juncture, it remains to be seen how similar ESCs and iPSCs truly are and 
whether comparison to ESCs is even the best marker for potential application of iPSCs. 
What is clear is that clinical application of human iPSCs will require improvements in 
generation and maintenance of iPSCs as well as frequent assessment of genomic stability. 
1.2.3 Differentiation of iPSCs 
Human iPSCs have now been used to generate a variety of cell types, for example 
insulin-producing pancreatic cells (74), adipocytes (75), and motor neurons (76). 
Recently, a group has reported generation and transplantation of human iPSC-derived 
retinal pigmented epithelium into mice and demonstrated improved visual function and 
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no tumor development over their lifetimes (77). Generation of lung cells from pluripotent 
cells have been approached in various ways. Wang et al., for instance, reported the 
derivation of alveolar type II cells from human ESCs that were stably transfected with an 
ATII-specific surfactant protein C promoter-neomycin transgene; the ESCs were 
spontaneously differentiated and selected for neomycin-resistant ATII cells (78).  
Another approach to differentiation is one that attempts to recapitulate, in a step-wise 
manner with exogenous factors, the normal embryonic development of the desired cells. 
Using this approach, two independent groups reported differentiation of mouse ESCs and 
iPSCs into early multipotent Nkx2.1+ cells (which developmentally give rise to lung and 
thyroid) and airway progenitor cells. Longmire et al. seeded decellularized mouse lung 
tissues with these mouse ESC-derived Nkx2.1+ cells and showed engraftment of cells that 
lost Nkx2.1 expression but expressed alveolar type I protein T1α (79). Mou et al. also 
differentiated mouse ESCs into Nkx2.1+ cells and showed that these cells were capable of 
giving rise to basal, Clara, ciliated, and goblet cells when subcutaneously engrafted into 
immune deficient mice; human ESC-derived Nkx2.1+ cells only showed evidence of 
basal cell differentiation when likewise transplanted (80). Recently, Wong et al. reported 
the derivation of tissue from human iPSCs and ESCs that they claim to be mature airway 
(81). In this report, they noted the presence of tight junctions as well as the apical 
localization of CFTR by immunofluorescence. Furthermore, in a functional assay for 
CFTR, they evidenced that the generated cells include appropriately expressed and 
functional CFTR.  
1.3 Genetic Correction of iPSCs 
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Gene therapy is commonly accomplished by viral delivery of a copy of the correct 
gene. Though gene therapies using randomly integrating virus to deliver the transgenes 
have been successfully applied in clinical trials for treating X-SCID (82) and Chronic 
Granulomatous Disease (CGD) (83), these promising results are overshadowed by some 
of the treated patients acquiring leukemia, in the case of the X-SCID treatments, or 
myelodysplasia, in the case of CGD. In both instances, these adverse effects resulted 
from random integration of the transgene adjacent to proto-oncogenes.  
In principle, site-specific integration of the correct gene would circumvent 
complications arising from random integration. Gene editing by homologous 
recombination allows researchers to edit in a site-specific manner. The goal of such site-
specific correction is to alter just a couple of bases of the 6 x 109 base pairs (bp) in a 
diploid human genome. Gene targeting and editing by homologous recombination can 
either be targeted to a safe harbor site (a constitutively expressed gene, disruption of 
which does not perturb normal function of the manipulated cell) or to the particular locus 
where the disease-conferring mutation is found. The latter is arguably favorable over the 
former because it does not generally require the full coding sequence nor regulatory 
sequences. Instead, in the latter case, only the mutations are corrected and expression of 
the gene should still be regulated by all the transcriptional regulatory elements of the 
endogenous gene.  
However, homologous recombination, regardless of site, happens infrequently –
typically 10-7 to 10-5 in mouse ESCs (84). Fortunately, a double-strand break (DSB) at the 
target site can increase site-specific gene targeting events up to 1000-10,000 fold (85, 86). 
DSB-mediated gene editing can be achieved by homology directed repair (HDR), 
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provided that there is a template of sufficient homology to the region immediately 
adjacent the DSB. In the absence of a homologous donor, non-homologous end joining 
(NHEJ) can be utilized to introduce mutations. After pioneering work by Jasin and 
colleagues in utilization of meganucleases like I-SceI to create site-specific DSBs for 
gene editing (87), researchers have been investigating other DNA nucleases that can be 
easily customized to any gene of interest. Currently, one of the most widely studied 
sequence-specific nucleases are zinc finger nucleases (ZFNs). 
1.3.1 Zinc finger nucleases 
A zinc finger nuclease is a fusion of zinc finger proteins to the cleavage domain 
of FokI (FIGURE 1.3a) (88). FokI is an endonuclease consisting of an N-terminal DNA-
binding domain and a C-terminal domain with nonspecific cleavage activity.  The zinc 
finger proteins (ZFPs) are a class of DNA-binding proteins, with each ZFP interacting 
with three nucleotides and acting as relatively independent modules (89). Initially, ZFNs 
were designed to bind a predetermined site of 9-12 bp by linking 3-4 zinc finger proteins 
together. Because FokI requires dimerization for cleavage, ZFNs work as a pair with each 
half-site (ZFN-L and ZFN-R) binding on opposite strands and separated by a space of 5 
or 6 bp to allow for optimal dimerization of the FokI domains (90).  
1.3.2 Specificity and optimization of ZFNs 
Specificity of ZFNs, then, is conferred by two sets of specific sequences (for a 
pair of ZFN, each with 3 zinc finger proteins for example, this is two sets of ~9 bp for a 
total of ~18 bp) and the probability that these two sets are in close enough proximity to 
allow dimerization of the FokI domains. Still, staining ZFN-treated cells with antibodies 
against proteins, like 53BPI, that are recruited to DNA damaged foci for repair reveals  
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FIGURE 1.3 Zinc Finger Nucleases (ZFNs) can create site-specific double strand 
breaks to induce genome modifications. a) ZFNs are bioengineered by linking 3 or 
more zinc finger DNA binding domains (4 shown above), which each recognizes and 
bind 3 specific bases, with the sequence-unspecific cleavage domain of FokI, which 
requires dimerization for activity. Functional only as a pair, ZFN specificity is then 
conferred by 9+ sequences on one side or “arm”, 9+ sequences on the other arm, and the 
need for the two arms to be close enough in proximity to provide a spacer region in 
which the two FokI domains can dimerize and cut. b) Early configurations of ZFNs could 
become active by any dimerization of two ZFNs: ZFN-L/ZFN-L or ZFN-R/ZFN-R, as 
well as the intended ZFN-L/ZFN-R. Newer ZFNs have FokI domains that have been 
modified such that they act only as obligate heterodimers; only a ZFN-L/ZFN-R 
configuration is functional, thereby increasing specificity. c) Double strand breaks can be 
repaired by two means: non-homologous end joining (NHEJ), which is error prone 
(illustrated as the introduction of a mutation depicted in black), or homology directed 
repair (HDR), which requires a homologous template (shown in blue).  
 
 
 
 
 
 
 
 
  
 
17
 
 
 
 
  
  
 
18
tens of foci when there should only be two (if there is biallelic cutting), thus implicating 
unintended ZFN effects (91, 92). By allowing up to 2 mismatches per half-site in the 
targeted binding sequence for ZFNs targeting the CCR5 gene, which encodes a major 
coreceptor for HIV-1 entry, Perez et al. found that the ZFNs also modified two other sites, 
one of which is the closely related CCR2 gene (93). Furthermore, it has been 
demonstrated that there is ZFN-induced toxicity due to binding infidelity (and subsequent 
cleavage) (94-96).  
For therapeutic purposes, then, it is pertinent to reduce ZFN off-target activity and 
toxicity. To address this issue, some groups have increased the number of zinc finger 
proteins linked to make one ZFN (97). Hockemeyer et al., for example, used ZFNs 
containing 4-6 zinc finger proteins for a combined recognition for the ZFN pair of 24-36 
bp (98). In addition, although ZFNs are modular in design, the binding specificity of the 
individual ZFPs have been shown to be context-dependent, i.e. affected by adjacent ZFPs. 
Thus, increased DNA-binding specificity has been achieved by optimization of adjacent 
ZFP pairs, rather than as individual ZFPs (99). 
Other factors may also play a role in defining specificity of a ZFN. For example, 
two groups have demonstrated that decreases in ZFN concentration also decrease off-
target cutting. Gupta et al. found that putative off-target sites that were actually cut share 
common characteristics with the intended target sequence: conservation of guanines 
(100). In putative off-target sites that were not cut, these same positions were found more 
diverse. Pattanayak et al. found that suboptimal molecular interactions at particular target 
site positions in one half-site led to reduced tolerance of mutations in the other half site, 
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even at other positions within the same half-site (101). Together, these results suggest 
ways that zinc fingers can be engineered for higher specificity.  
Alternatively, the ZFN structure can be altered at the cleavage domain to increase 
specificity. As mentioned before, the FokI nuclease domain requires dimerization to be 
active. ZFNs are created to function as a pair, each ZFN with its own unique DNA-
binding domains; however, theoretically, homodimers of ZFN-L/ZFN-L or ZFN-R/ZFN-
R can also bind and cleave. Three groups have reported alteration of the nucleases’ 
dimerization interface to create variants that are functional only as obligate heterodimers 
(FIGURE 1.3b), thus abrogating the risk of cutting by homodimers while maintaining the 
advantages of cleavage that is dimerization-dependent (91, 92, 102).  
1.3.3 ZFN-mediated homology directed repair 
Donor-free delivery of ZFNs can be used to disrupt genes by inducing NHEJ (84, 
95). Alternatively, gene addition can be achieved by providing an appropriate donor 
template along with the ZFNs, taking advantage of HDR; such approach has been used to 
correct genetic diseases (FIGURE 1.3c). In fact, gene correction can be accomplished 
directly at the mutated gene (103) or at a safe-harbor locus like AAVS1 (104, 105). 
Furthermore, biallelic modifications can be made (93, 106).  
The gene targeting efficiency may depend on several factors including 
accessibility of the target gene and how the ZFNs and donor are delivered (98). In 
addition, the design of the donor definitely plays a role. Pruett-Miller et al. optimized 
their donor template by altering the sequences recognized by the ZFNs to prevent ZFN 
cutting of the newly repaired gene (92). Highly influential to the efficacy of the donor as 
a template for HDR is the extent of homology between the targeted locus and the 
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targeting (donor) vector. Most of the information relevant to length and extent of 
homology between donor and target locus come from standard HR in the absence of an 
introduced sequence-specific DSB. It seems that the total length of DNA sequence 
present in the donor is not as important as the amount of homology between it and the 
target sequence (107). A mere 2-fold increase in homology increases gene targeting 
frequency by 20-fold (108). Waldman and Liskay found that there was little difference in 
recombination frequency between sequences with 232 bp of uninterrupted homology and 
the frequency of recombination between two sequences with four mismatches distributed 
throughout while still maintaining a 232 bp stretch of homology (109). Similar 
experiments studying the effects of donors with various amounts of heterology on 
recombination frequency in the presence of an introduced DSB (via SceI) support these 
conclusions (110). 
1.3.4 ZFN-mediated correction of iPSCs 
Recently, there have been multiple reports of ZFN-mediated gene editing of 
iPSCs (extensively reviewed in (111)). Hockemeyer et al. have used ZFNs to target both 
silenced and expressed genes including the safe harbor AAVS1 locus (98). Another locus, 
the CCR5 locus, has been routinely used for stable transgene expression in a site-specific 
manner (112). ZFNs have also been used to create mutations. Soldner et al., for instance, 
used ZFNs to introduce two different point mutations associated with Parkinson’s disease 
to create an in vitro disease model (53). Alternatively, ZFNs can be used in iPSCs to 
correct diseases like α1-antitrypsin deficiency (113), sickle cell disease (114), and α-
thalassemia (115). For example, to correct α-thalassemia, Chang and Bouhassira 
accomplished gene correction by insertion of a goblin transgene into the AAVS1 safe 
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harbor site of iPSCs and showed that these corrected iPSC were able to give rise to 
erythroid cells. Such reports suggest that ZFN-mediated gene edits in iPSCs do not alter 
differentiation potential.  
1.3.5 Other tools for targeted genome editing 
 Gene targeting facilitated by ZFNs and homing nucleases, a meganuclease like I-
SceI, have been well documented. Still, the search for more easily engineered, cheaper, 
and safer tools for enhancing gene targeting continues. Recently, transcription activator-
like effector nucleases (TALENs) and RNA-guided Cas9 nucleases have been added to 
that list. Due to their flexibility in design, both TALENs and Cas9 are reported to be 
capable of targeting more of the genome than ZFNs and have now been used to 
genetically modify human iPSCs (116-118). Ultimately, a variety of factors will 
determine which nuclease platform will be used for a given therapeutic application – 
principally the efficiency of cleavage and absence of off-target effects. 
1.3.6 Gene correction of CF 
Several factors make CF a prime candidate for targeted genome correction: 1) CF 
is a monogenic disease, and 2) it follows recessive Mendelian inheritance with carriers 
showing no clinical manifestations of CF so correction of just one allele would restore 
carrier state. To ensure appropriate control from endogenous transcriptional regulatory 
elements, an endogenous approach (vs random integration or safe harbor) would be more 
applicable. One option for endogenous correction of CF is to knock-in CFTR cDNA to 
provide a full copy of the correct gene that would correct a broad range of CF mutations. 
However, 70% of CF alleles have a deletion of just three nucleotides, ∆F508 (119); thus 
correction of this particular mutation would still benefit a majority of CF patients.  
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Restoration of the three nucleotides missing in ∆F508 CFTR should restore 
proper protein folding, allowing for proper glycosylation, maturation, and thus transport 
to the Golgi and, then, to the cell surface. Correction of CFTR folding and maturation can 
be detected by western blot. Fully mature CFTR protein is ~170 kDa and is sensitive to 
deglycosylation by N-glycosidases, whereas the ∆F508 mutation results in an immature 
core-glycosylated protein that is ~140 kDa. 
1.4 Objectives and Hypothesis 
We hypothesize that we can utilize these two novel technologies – 
reprogramming of somatic cells by defined factors and ZFN-mediated gene editing of 
iPSCs – to provide the foundation for an alternative to conventional gene therapy 
approaches for treating Cystic Fibrosis. We hypothesize that patient-specific iPSCs can 
be generated from fibroblast cells obtained from CF patients and corrected to restore 
wild-type CFTR expression in iPS-derived lung cells. To accomplish this, we aimed to 1) 
generate CF-specific iPSCs, 2) correct the disease-conferring mutation, and 3) 
demonstrate that genetic correction will lead to restored protein expression. 
1.4.1 Specific Aims 
To accomplish our goals, three specific aims were proposed: 
SAi. Generate a line(s) of induced pluripotent stem cells (iPSCs) from primary 
fibroblasts derived from Cystic Fibrosis patients. Fibroblast cell lines derived from 
patients with CF were reprogrammed by ectopically expressing reprogramming factors, 
delivered by viral means. To assess similarity to embryonic stem cells, reprogrammed 
cells were characterized based on cell and colony morphology, expression of stem cell 
markers by immunohistochemistry, expression of stem cell genes via real-time PCR 
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assay, and the ability to form teratomas in immunodeficient mice injected with the human 
iPSCs.  
SAii. Correct the disease-conferring genetic mutation in the iPSCs using zinc 
finger nuclease (ZFN) -mediated homologous recombination.  We employed ZFNs 
targeting exon 10 of CFTR to induce homologous recombination of the endogenous, 
deleted sequences with a donor containing the wild-type sequences to correct the 
mutation in reprogrammed cells. To demonstrate successful gene correction in a targeted 
manner, PCR and Southern blot analysis were used to confirm site-specific integration 
and ensure no off-target insertion site was generated.  
SAiii. Determine restored CFTR expression in lung cells differentiated from 
genetically corrected iPSCs. To demonstrate that our method of correcting CFTR results 
in restored CFTR expression, we compared the forms of CFTR that are generated from 
lung cells derived from uncorrected vs. corrected iPSCs. Correction of the mutation 
should result in proper CFTR glycosylation, detectable by western blot. To generate lung 
cells, we utilized both spontaneous and more directed in vitro differentiation.  
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Chapter 2: Materials and Methods 
2.1 Cell lines and culture 
Through Coriell Repository (Cambridge), we obtained CF primary fibroblast line 
GM04320 from a 17 year old male reported to be homozygous ∆F508 CFTR and 
showing pancreatic insufficiencies as well as advanced pulmonary disease. The CFTR 
mutation was interrogated by PCR amplification and sequencing (TABLE 1). CF 
fibroblasts and murine embryonic fibroblasts (MEFs; CF-1 mouse strain, Charles River) 
were maintained in DMEM supplemented with 10% FBS, 2 mM non-essential amino 
acids (NEAA), and 2 mM L-glutamine (all from Invitrogen). Fibroblast media is herein 
denoted as FM. 
Human embryonic stem cell (ESC) line WA09 and transgene-free iPSC lines 
RC202 and RC204, which were provided by Darrel Kotton (63), were maintained in ESC 
media as outlined by National Stem Cell Bank protocol SOP-CC-001C. The cells were 
fed daily with DMEM-F12 (Invitrogen) supplemented with 20% Knockout Serum 
Replacer (Invitrogen), 2 mM each of L-glutamine and NEAA, 55 µM 2-mercaptoethanol 
(Sigma), and 4 ng/ml basic fibroblast growth factor (bFGF; Invitrogen). The CF-iPSCs 
that were generated in our laboratory were similarly maintained but with 40 ng/ml bFGF. 
All cells were cultured, except where denoted, in media under humidified conditions at 
37°C and 5% CO2. 
 Routinely, ESCs and iPSCs were passaged in clumps every 5-6 days. To passage, 
the cells were washed twice with dPBS (+ calcium / + magnesium), incubated in 1 mg/ml 
Collagenase Type IV (Invitrogen) for 3-5 minutes (enough for the edges of the colonies 
to begin to flip upwards but not enough for the whole colony to lift off the plate), and 
  
 
25
TABLE 1 List of Primers. Where applicable, expected amplicon length and annealing 
temperatures used are also indicated. 
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then gently washed twice with dPBS. Using a 5 ml pipette tip, the cells were scraped to 
cut into pieces and then gently pipetted up and down. The cells were split 1:12 – 1:6.  The 
cells were plated on 0.1% gelatin-coated (Sigma) plates pre-seeded (24 hours) with 
irradiated MEFs (iMEFs) as a feeder layer at ~ 2x105 cells/well in a 6-well plate. For 
certain applications, ESCs or iPSCs were maintained on Matrigel. In such cases, plates 
were coated with 30% Matrigel (Becton Dickinson) at 4°C overnight or for 3+ hours at 
37°C. The ESCs or iPSCs were treated with dispase (STEMCELL Technologies), 
manually broken into pieces, and split 1:3 or 1:4.  
2.2 iPS Generation 
pMXs-based retroviruses expressing reprogramming factors OCT4, SOX2, KLF4, 
c-MYC, and NANOG was provided by K. Plath and obtained through Addgene (56). To 
generate pMXs-GFP, the ORF for GFP was amplified by PfuUltra Hot Start DNA 
Polymerase AD (Agilent Technologies) from CCR5-pgk-gfp with primers (TABLE 1) 
containing novel EcoRI and NotI restriction enzyme sites. This amplicon was digested 
and cloned into the pMXs backbone, obtained by EcoRI and NotI digestion of pMXs-
KLF4. The protocol for VSV-G pseudotyped retroviral vectors was adopted from Park 
and Daley (120). For each reprogramming factor, two 150 mm plates were seeded with 
approximately 7 million Plat-GFP Retroviral Packaging Cell Line (Cell Biolabs, Inc.). 
The next day, each plate of Plat-GFP cells was transfected with 6.25 µg of the pMX 
retroviral vector and 0.9 µg pCMV-VSV-G (provided by B. Weinberg and obtained 
through Addgene) (121) in a total volume of 30 ml media (DMEM, 10% FBS, 10 µg/ml 
blasticidin) containing 50 µl Fugene 6. Virus-containing media (a total of 60 ml per 
vector) was collected 48 hours after transfection, filtered through a 0.45 µm filter into a 
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polyallomer centrifuge tube, and spun down at 26K rpm for 2 hours (in a SW288 
Beckman rotor). The pelleted virus was then resolubilized in 600 µl DMEM/F12 (for a 
100x concentration). The virus titer was determined by infecting primary human 
fibroblasts with pMXs-GFP (simultaneously packaged and concentrated) and assessing 
the frequency of GFP-expressing cells by flow cytometry.  
 To reprogram fibroblasts (summarized in FIGURE 2.1), cells were plated at 105 
cells per well of a 6-well plate on day 0. On days 1 and 2, the cells were transduced with 
all five reprogramming factors by spinfection (200 g for 30 minutes) at a multiplicity of 
infection of 21.5, in FM supplemented with protamine sulfate (10 µg/ml). Fifty-six hours 
after the initial transduction, the transduced cells were trypsinized and transferred (1:1) 
onto gelatin-coated plates previously seeded with iMEFs; 24 hours later, the media was 
switched from fibroblast media to ESC media containing 40 ng/ml bFGF, as indicated 
above. Starting on day 12, the cells were fed with hESC media that had been pre-
conditioned on iMEFs. The cells were re-fed daily.  
Approximately 16 days after transduction, we began to identify individual iPSC-
like colonies based on morphology. Live-cell staining with anti-TRA-1-60 monoclonal 
antibody (mouse IgM; 1:200; Stemgent) followed by Alexa 488 goat anti-mouse IgM 
(1:250; Invitrogen) was used to identify reprogrammed colonies. When TRA-1-60 
expressing colonies (Tra-1-60+) were of sufficient size (generally, taking up at least ¾ of 
the field when looked under the microscope at 10x magnification), each clone was 
manually cut into 4-9 pieces, depending on size, with a glass, end-closed pipette. The 
pieces were then collected and seeded into a well of a 12-well plate (one colony per well) 
pre-seeded with iMEFs and ESC media supplemented with 10 uM Y-27632 (Alexis 
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Biochemicals). Depending on recovery rate and growth, these could then be subsequently 
split 1:2 to 1:4 at next passage. In total, we clonally picked 32 colonies that were TRA-1-
60+, nine of which were expanded and cryopreserved. Based on colony growth and 
morphology, we selected two clones (iPS 17 and 28) for more extensive characterization. 
2.3 iPS Characterization 
In addition to live-cell staining for TRA-1-60, potential iPSC clones were also 
characterized via live-cell staining for TRA-1-81 (mouse IgM; 1:200; Millipore). Co-
expression of OCT4 and SSEA4 was assessed according to the WiCell protocol SOP-CH-
102B and analyzed by flow cytometry on an LSR-II running BD FACSDiva Software 
(Becton Dickinson). Generally, after excluding CD29+ MEFs, the presence of ≥ 90% 
OCT4+/SSEA4+ double positive cells (of total population excluding MEFs) was 
considered a relatively undifferentiated population with minimal spontaneous 
differentiation. 
Alkaline phosphatase activity was accessed using VECTASTAIN ABC-AP Kit 
(Vector Laboratories). Briefly, after washing cells twice with DPBS, the cells were fixed 
for at least 30 minutes with 2% paraformaldehyde in DPBS. The paraformaldehyde was 
removed and replaced with 2 ml per well of a 6-well plate with substrate solution 123 for 
30 minutes to 2 hours in the dark, per manufacturer’s protocol. The cells were then 
washed with DPBS containing 0.1 Tween-20 for 5 minutes and rinsed with DPBS.  
Karyotyping of CF-iPSC clones was performed at Texas Children’s Hospital 
Clinical and Research Cytogenetic Laboratory, where they evaluated approximately 20 
metaphase cells per cell line. 
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FIGURE 2.1 Reprogramming of CF-specific fibroblasts. Human fibroblast cells 
derived from a patient with CF were transduced with retrovirus to deliver the 
reprogramming cocktail (OCT4, SOX2, KLF4, c-MYC, and NANOG) in fibroblast 
media. After 56 hours, the cells were transferred onto gelatin-coated plates pre-seeded 
with irradiated mouse embryonic fibroblasts (iMEFs; shown as light brown), still in 
fibroblast media, and at sufficiently low density to enable clonal growth of individual 
cells surviving the infection and transfer. Twenty-four hours after transfer, when the 
transduced cells plated, cells undergoing reprogramming were selected for in ESC media; 
16 days later, colonies arising out of the selection were clonally picked and transferred to 
iMEF-seeded 12-well plates for further expansion and characterization.  
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To assess the ability to generate teratomas, iPSCs were first cultured on 30% 
Matrigel and fed daily with mTESR (STEMCELL Technologies) to remove iMEFs. 
Between 2 and 3 million iPSCs were injected into the kidney capsule or testis of six-
weeks old Fox Chase SCID beige mice (Charles River) and observed weekly for tumor 
growth. This was performed on 3 mice per cell line. The tumors were removed around 6 
– 8 weeks after injection, paraffin embedded, prepared for histological examination by 
hematoxylin and eosin, and analyzed (Applied Stem Cell Inc.). 
Qualitative RT-PCR was used to assess if the retroviral transgenes used in 
reprogramming had been silenced. To do this, total RNA was isolated from iPSCs or 
WA09 cells (for comparison) with the RNeasy Kit (Qiagen) and cDNA synthesized using 
Improm-II Reverse Transcription System (Promega). Levels of expression of 
reprogramming genes were determined by SYBR Green (Applied Biosystems) 
incorporation using primers (TABLE 1) designed to distinguish endogenous (one primer 
of each set includes 3’ UTR) from total (both primers in coding regions) expression of 
each reprogramming gene. The RT-PCR was performed in two replicate samples for each 
cell line in a 96-well format on the ABI 7900, and expression levels were normalized to 
that of GAPDH.  
Additionally, mRNA expression levels of 44 human ESC-specific genes in our 
CF-iPSCs were assessed by qRT-PCR using RT2 Profiler PCR Array Human Embryonic 
Stem Cells (SABiosciences) per manufacturer’s protocol. The array also included Beta-2-
microglobulin, Hypoxanthine phosphoribosytransferase 1, Ribosomal protein L13a, 
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and beta-Actin. For comparison, 
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expression levels in human ESC line WA09 was simultaneously assessed. Analysis was 
performed using the data analysis template provided by the manufacturer.  
2.4 Correction of CF-iPSCs 
A potential ZFN target in exon 10 upstream of the ∆F508 mutations was 
identified and ZFNs were bioengineered by Sangamo Biosciences to bind and create a 
DSB. The efficacy of cutting at the targeted loci by ZFN pair 12987 (recognizing 
TAGAAGtGAAGTCTGG) and 9940 (ATTATGGGAGAACTG) in the form of 
expression plasmid or in situ generated RNA was determined by Cel-1/Surveyor assay 
(91, 93). To generate the RNA for each ZFN, 1 µg of XbaI linearized plasmid DNA was 
used as per protocol to generate capped RNA using MessageMAX™T7 ARCA-Capped 
Message Transcription Kit (CellScript Inc.). This was then treated with DNaseI, a 
poly(A) tail was added by Poly(A) Polymerase Tailing Kit (Epicentre), and the resulting 
product was purified by MegaClear Kit (Ambion).  The size, quality, and concentration 
of in vitro transcribed RNA was determined by Agilent Bioanalyzer. 
 The Cel-1 assay takes advantage of the infidelity of non-homologous end joining 
as the default repair mechanism for DSBs in the absence of a homologous template or 
donor (FIGURE 2.2). Two million dissociated iPSCs are first transfected with equal 
amounts of each ZFN and plated onto gelatin-coated plates seeded with iMEFs and 
incubated at either 37°C. Two days later, total DNA was isolated from the transfected 
cells and the 195 bp around the ZFN-targeted region was PCR amplified (TABLE 1). 
After denaturation and reannealing of the amplicon (95°C for 10 minutes; cool to 85°C at 
-2°C/sec; cool to 25°C at -1°C/sec; hold at 4°C), which results in a mixture of 
homoduplexes (of either two strands with the same NHEJ-induced mutation or two  
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FIGURE 2.2 Efficacy of ZFN cutting can be determined by Cel-I analysis. To assess 
efficiency of cutting by ZFNs at the target loci, equal amounts of each ZFN are delivered 
to dissociated induced pluripotent stem cells. DNA is isolated from the cells, some of 
which was cut by the ZFNs and subsequently repaired by mutation-inducing NHEJ (red) 
while others were not cut by the ZFNs and thus wt (blue). The specific target is amplified 
and the amplicon is dissociated and re-annealed. This results in a mixture of duplexes 
with two wt strands, two mutated strands, or one mutated and one wt strand. The latter 
heteroduplex is recognized and leaved by Surveyor nuclease. By resolving undigested 
and digested material, efficacy can be quantified as a measurement of the ratio of cut 
band to total band intensity.  
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strands that were not cut by the ZFNs and thus wt) and heteroduplexes of NHEJ-induced 
mutated and ZFN-uncut strands. Surveyor nuclease was added to the mix to cut any 
heteroduplexes. This was then resolved on 10% TBE gels at 100V for 1 hour. Surveyor 
nuclease-digested heteroduplexes would result in two bands, 110 and 85 bp, quantifiable 
using a phosphoimager. The efficacy of cutting is a measurement of the relative ratio of 
digested heteroduplexes to total amount of undigested and digested as determined by the 
formula: (1-√(uncut/total)) x 100.    
The donor plasmid (FIGURE 2.3) used to facilitate HDR was generated by 
amplifying from BAC gDNA (RP11-1152A23) approximately 1.6 kb CFTR sequences 
flanking the intended ZFN cut site (TABLE 1). This amplicon was cloned into the pSC-B 
as per StrataClone Blunt PCR Cloning Kit (Stratagene). An AvrII site was introduced via 
Quikchange II Site-Directed Mutagenesis (Agilent Technologies) in intron 10, 128 bases 
-downstream of the end of exon 10. By Quikchange Multi Site-Directed Mutagenesis 
(Agilent Technologies), two silent mutations were introduced in the sequences 
recognized by the right ZFN and another silent mutation was introduced 22 bases 
downstream of the sequences restoring F508. This latter silent mutation created a novel 
ClaI site. A selection marker conferring phosphoglycerate kinase-driven puromycin 
resistance and thymidine kinase sensitivity (pgk-puro-TK) was amplified from pPthc-
Oct3/4 (received from Dr. Naoki Nakayama) (122) using primers (TABLE 1) containing 
loxP sites and flanked by AvrII sites and Phusion Hot Start II high fidelity DNA 
polymerase (New England Biolabs) in a way such that the orientation of the selection 
cases was antisense to CFTR. This amplicon was cloned into the pSC-B backbone  
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FIGURE 2.3 Donor for homology directed repair of CF. Approximately 1.6 kb of 
wild-type sequences for CFTR was used as homology arms and a 2.6 kb selectable 
marker flanked by loxP sites was cloned into intron 10, downstream of exon 10 splice 
donor sites. The selectable marker was cloned in such that expression is antisense to that 
of CFTR. To disrupt recognition (and cutting) of the donor by the co-delivered ZFNs, two 
silent mutations were introduced in the sequences that would be normally recognized by 
ZFN-R (circles). A third change was made to the wild-type sequences: a ClaI site was 
introduced via silent mutation approximately 20 bases downstream of the wild-type 
sequences to correct ∆I507/∆F508 (star).  
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containing CFTR homology sequences at the AvrII site by In-Fusion Cloning (Clonetech 
Laboratories). The donor plasmid was confirmed by sequencing. 
Delivery of ZFNs and/or donor plasmid to cells was accomplished via 
nucleofection using Human Stem Cell Nucleofector Kit 1 (Lonza), adapting manufacturer 
protocol.  For each condition, two million human ESCs were dissociated into single cell 
suspension via Accutase (STEMCELL Technologies) treatment. Incubating the iPSCs in 
Accutase for 2-3 minutes at 37°C results in most of the MEFs lifting off the plate while 
the iPSC colonies remained loosely attached with cells rounding up, making them easily 
dissociated by gentle pipetting with PBS after the Accutase was removed. The cells were 
centrifuged in microfuge tubes at 200g for 5 minutes and the PBS aspirated. The cells 
were then resuspended in 100 µl of the supplemented nucleofection solution. This was 
then added to another microfuge tube containing the various DNAs/RNAs combinations: 
1 or 2 ug of each ZFN DNA expression plasmid or 1.5 or 3 ug of each ZFN RNA plus 4 
or 8 ug of the donor (TABLE 2). Controls for ZFN cutting alone did not include donor; 
controls for random integration of donor sequences, in the absence of ZFN-mediated 
cutting, included only donor without ZFNs. This mixture was then placed into the 
cuvettes provided and nucleofected using the Amaxa program A23. Subsequently, 500 ml 
of ESC media containing the appropriate amount of bFGF and supplemented with 10 uM 
Y-27632 was gently added to the nucleofected mixture, which was then split between two 
wells of a 6-well plate pre-seeded with puromycin-resistant iMEFs in supplemented ESC 
media. After 24 hours, the cells were fed daily. Puromycin selection (0.5 ug/ml) began 4 
days post nucleofection and, 2-5 days later, puro-resistant colonies were clonally picked  
 
 TABLE 2 Matrix of correction experiments.
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in the same manner as isolation of potential reprogrammed cells and expanded (still 
under puromycin selection, generally, for 3-4 passages).  
2.5 Analysis of targeted clones 
Targeted integration of the donor was assessed first by PCR using two sets of 
primers (TABLE 1). One primer of each set recognizes CFTR sequences outside the 
homology arms found in the donor and the other primer of each set recognizes sequences 
in the drug selection cassette. Thus, the primers were designed such that amplification 
would occur only in the case of integration of the donor at this locus. The 5’ amplicon 
was produced using Expand Long Template PCR (Roche), and the 3’ amplicon was 
produced using GoTaq Green Master Mix (Promega). To confirm correction of the 
mutation, the 5’ amplicon was sequenced. To determine which allele was uncorrected, 
the unmodified allele was preferentially amplified using Expand Long Template PCR and 
primers that recognized CFTR sequences outside the donor homology arms so that the 
unmodified allele amplicon was ~1.9 kb while the modified allele amplicon was ~4.5 kb 
(TABLE 1). The unmodified allele amplicon was gel isolated via Nucleospin Gel and 
PCR Cleanup (Macherey Nagel) and sequenced. 
 To assess expression of the corrected CFTR mRNA, RNA was isolated with 
RNeasy kit (Qiagen) and cDNA synthesized using Improm-II oligo dT kit (Promega). 
The CFTR cDNA was amplified from either the border of exon 8-9 to exon 11 or from 
exon 9 to exon 13 (TABLE 1) and subsequently sequenced. 
Southern blotting was used to assess site-specific integration of the donor. A 
radio-labeled DNA probe was generated by digesting the donor plasmid with NdeI and 
SpeI and separated on 0.8% agarose gel. A 2.3 kb fragment containing pgk-puro-TK 
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sequences was gel purified and labeled with [alpha-32P]dCTP using Prime-It II Random 
Primer Labeling kit (Agilent Technologies) per manufacturer’s instruction. Genomic 
DNA (25 mg), digested with SpeI overnight and purified by phenol/chloroform extraction, 
was resolved on 1% agarose gel, transferred to a Nytran Super Charge membrane 
(Schleicher and Schuell), and hybridized with 32P-labeled probe. The membrane was 
exposed and image scanned using a phosphorimager system (Molecular Dynamics). 
2.6 Cre-mediated excision of selectable marker 
Excision of the loxP-flanked selectable marker was accomplished via transient 
expression of Cre-recombinase. Four µg of either pBS513 EF1alpha-cre [Addgene 11918 
provided by B. Sauer] (123) or pCAG-Cre [Addgene 13775 provided by C. Cepko] (124) 
was delivered to 2 million corrected iPSCs (previously dissociated into a single cell 
suspension via Accutase) by nucleofection as described previously in Section 2.4 and 
plated onto irradiated MEFs. Successful excision was determined by either FIAU 
resistance (1 µM; Moravek Biochemicals) or by first picking and expanding individual 
clones in replicates and identifying puromycin sensitive clones. Clones that were FIAU 
resistant and/or puromycin sensitive were tested molecularly as confirmation of excision 
of selectable markers using the same primers used to determine targeted integration in 
Section 2.5. Cre-excision was confirmed molecularly by PCR using primers that anneal 
to sequences outside donor homology, yielding three possible amplicons: 1) a 4.4 kb 
amplicon corresponding to the modified allele, 2) a 1.8 kb amplicon to the modified allele 
after excision, and 3) a 1.8 kb amplicon to the unmodified allele. The modified allele post 
excision was distinguished from the unmodified allele by ClaI digestion. 
2.7 In vitro differentiation 
  
 
39
For differentiation into definitive endoderm, precursor to the epithelial lining of 
the forgut, we adapted the protocol of D’Amour et al. (125). To induce differentiation, 
iPSCs grown on iMEFs were cultured in RPMI supplemented with 100 ng/ml Activin A 
(R&D Systems) and varying concentrations of fetal bovine serum (0% on day 0, 0.2% on 
day 1, and 2.0% every day thereafter). RNA was isolated at various time points and 
analyzed by RT-PCR for expression of CFTR (primers spanning exons 9 through 13) and 
SOX17 (TABLE 1), a marker of definitive endoderm. 
In 2009, Van Haute et al. described the differentiation of human ESCs into lung 
epithelial-like tissue that showed increased FOXJ1 and β-tubulin mRNA expression and 
evidence for ATII expression via immunostaining (126). Trying to replicate their findings, 
we took two iPSC lines that had been corrected and the uncorrected iPSC line and 
followed their protocol. Cells were collagenase treated for 7 minutes so that the colonies 
rounded up but still remained loosely attached to the surface of the plate. We then seeded 
30 clumps, defined either as 30 rounded colonies or 30 pieces cut from colonies, onto 12 
mm hydrophilic PTFE Millicell cell culture inserts (0.4 µm; EMD Millipore) that were 
placed into gelatin and iMEF-coated 12-well plates with 600 ml ESC media outside the 
insert and 400 ml inside the insert. After 24 hours, the ESC media inside and outside the 
insert (liquid-liquid conditions) was changed daily. Four days after seeding the clumps, 
the media was switched to differentiation media (ESC media without β-mercaptoethanol 
or bFGF).  Media was changed daily for four more days still in liquid-liquid conditions, 
after which the cells were then cultured in air-liquid conditions with differentiation media 
only outside the insert. After 15 days, RNA was isolated and expression of GAPDH, 
SOX17, CFTR, and FOXJ1 was assessed by RT-PCR. 
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To establish NKX2.1-expressing progenitor cells, which give rise to lung and 
thyroid, we followed the directed differentiation protocol as described by Green et al. and 
Longmire et al. (79, 127). Prior to differentiation, the iPSCs were first adapted to single-
cell dissociation via TrypLE (Invitrogen) and cultured on Matrigel in mTeSR. To induce 
differentiation, embryoid bodies are first formed: the cells are treated with dispase until 
the edges of the colonies have rounded up, washed three times with IMDM (Invitrogen), 
and the colonies were broken into clumps of 10-20 cells in pre-warmed serum-free 
differentiation media (SFD) (128) supplemented with 10 µM Y-27632, 3 ng/µl BMP4, 
and 10 ng/µl Wnt3a.  These were then transferred to low attachment plates and incubated 
at 37°C, 5% CO2, and 5% O2 for 24 hours. Between days 1 and 4, the cells are fed every 
other day with induction media (SFD supplemented with 10 µM Y-27632, 0.5 ng/µl 
BMP4, 2.5 ng/µl FGF2 and 100 ng/µl Activin A). On day 4, expression of endodermal 
surface markers c-KIT and CXCR4 was assessed by flow cytometry (antibodies from 
Invitrogen). If we obtained populations of >70% double positive, we then proceeded with 
anteriorization; 60,000 to 80,000 single cells were plated into each well of a gelatin-
coated 24-well plate and cultured in SFD supplemented with 10 µM Y-27632, 200 ng/ml 
Noggin, and 100 ng/ml SB-431542. From day 6 until day 19, the cells were cultured in 
prewarmed ventralization media (SFD supplemented with 500 ng/ml FGF2, 100 ng/ml 
Wnt3a, 10 ng/ml FGF7, 10 ng/ml BMP4, 20 ng/ml EGF, and 100 nM Retinoic Acid). All 
reagents, unless noted otherwise, were obtained from R&D Systems. At indicated time 
points, cells were pelleted and stored for future protein or RNA isolation and analysis. 
The expression profile of differentiated cells was measured in triplicate using TaqMan 
probes from Life Technologies. Gene expression was normalized against housekeeping 
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gene 18S and compared to undifferentiated samples (TABLE 1). Total RNA from fetal 
lung and fetal thyroid samples (BioChain) was used for comparison. 
To detect CFTR protein, samples from day 19 of differentiation, along with Calu-
3 cells as a positive control, were lysed with 1% Triton X-100, 50 mM Tris HCl, pH 7.5, 
150 mM NaCl, 5 mM EDTA, and a protease inhibitor mixture (Roche) while on ice and 
centrifuged for 15 minutes at 6,000 g. After cell debris was removed, protein amount was 
quantified by BCA protein assay (Thermo Fisher). Total protein from differentiated 
samples (100 µg) and Calu-3 cells (10 µg) were treated with denaturation buffer (as 
described by New England Biolabs’ protocol for PNGase F) with or without PNGase F 
for 1 hour at 37°C. The reaction was stopped by adding 4x Laemmli sample buffer (Bio-
Rad) to the mixture. The protein (50 µg from differentiated samples and 5 µg from Calu-
3 samples) was then separated by NuPAGE SDS PAGE Gel System (Life Technologies) 
on 7% Tris-Acetate gel (Life Technologies), transferred onto Hybond-C nitrocellulose 
transfer membrane (Amersham Biosciences). The membrane was blocked in 5% milk for 
1 hour at room temperature and then incubated in mIgG2b 596 (1:1000; Cystic Fibrosis 
Foundation Therapeutics) overnight at 4°C. After washing with TBE and 0.1% Tween-20, 
the membrane was incubated in secondary HRP-linked anti-mouse IgG (1:5000; Cell 
Signaling Technologies) for 1 hour at room temperature before detection by 
chemiluminescense using Amersham ECL Prime. Anti-Calnexin polyclonal antibody 
(1:300; Abcam) along with secondary anti-rabbit IgG IRDye 800CW (LI-COR) was used 
as a loading control. Fluorescence intensities of the protein bands were measured with an 
Odyssey Quantitative Infrared Imaging System. 
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Differentiated cells were also immunostained to visualize FOXA2 and NKX2-1. 
Cells were fixed with 4% paraformaldehyde for 30 minutes and permeabilized with 0.2% 
Triton X-100 for another 15 minutes. The sample was then blocked in 4% donkey serum 
for 30 minutes and incubated in primary antibody (FOXA2 goat polyclonal antibody, 
1:100, Santa Cruz Biotechnology; NKX2.1 rabbit polyclonal antibody, 1:100, Abcam) at 
4 degrees overnight. The cells were then washed twice and incubated in secondary 
antibody (1:100) at room temperature for 2 hours. Cy3 donkey anti-rabbit (Jackson Labs) 
and goat anti-mouse Alexa 488 (Life Technologies) were used as secondary antibodies. 
2.8 Genome sequencing and analysis 
Complete genome and whole exome sequencing was performed and analyzed as 
previously described (to be published) 
Human iPSCs were first depleted of MEFs by passage on matrigel in 
MEF-conditioned media. Genomic DNA was extracted with the QIAprep 
Spin Miniprep Kit. DNA sequences were obtained as described previously 
using DNA nanoball amplification and combinatorial probe-anchor 
ligation sequencing (Drmanac et al. 2010; Lee et al. 2010). Possible de 
novo non-synonymous coding variants (NSCV) were analyzed and filtered 
based on two independent criteria (somaticScore and refScore) and then 
combined to generate the list in Table S2. Since each cell line was 
compared to the reference genome (GRCh37/hg19) we used the calldiff 
function with somatic option in CGA Tools to generate pairwise 
comparisons of our four cell lines. All NSCV with SomaticScore greater 
than -10 from the 8 pairwise comparisons were combined with NSCV 
which had a refScore greater than 60 (indicating the likelihood of being 
homozygous reference) in the mutant CF fibroblast cell line. The 
compendium of putative NSCV was examined across all four cell lines by 
loading evidence file based BAM files for each cell line into the 
Integrative Genomics Viewer (Robinson et al. 2011). We considered false 
NSCV to consist of variations in areas with poor coverage (<9 reads), seen 
in the CF mutant fibroblast (Gore et al. 2011), variations present at <10% 
frequency, and those duplicating nearby repetitive sequences. The 10% 
frequency is based on observations of loci with variant reads present at 
10% of total reads that were not called variant. Since the BAM files were 
generated from evidence files after de novo alignment, coverage was 
assessed indirectly based on calls in the masterVarbeta files; regions with 
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“no call” or “complex” in any of the cell lines. In other instances where 
there was no sequence data in the BAM files and a call of “hom ref”, we 
assumed homozygous reference sequence when coverage scores were 
positive.  
Exome Capture and Sequencing: 
Two micrograms of genomic DNA was submitted to Axeq Technologies 
for human exome capture sequencing using TrueSeq 62 Mb target 
enrichment 
(http://www.illumina.com/documents/products/datasheets/datasheet_truse
q_exome_enrichment_kit.pdf). Axeq Technologies performed sample 
validation, library preparation, exon enrichment, clustering and 
sequencing using illumina HiSeq 2000 Sequencer.  Approximately 
63,000,000 reads of an average size of 107 bp per sample was returned to 
us as two fastq files (one file per orientation). 
Read Mapping: 
Each pair of fastq files were aligned to human genome (hg19) using 
Novoalign (http://www.novocraft.com). All parameters were kept at the 
default settings, as recommended by Novocraft. SAMtools 
(http://samtools.sourceforge.net/) (Li et al. 2009) was used to sort the 
SAM files, create BAM files and generate their index files. Picard 
(http://picard.sourceforge.net/) was used to remove all the PCR duplicates 
from the BAM files.  The Genome Analysis Toolkit (GATK) (McKenna et 
al. 2010) was used for local realignments, base quality recalibration, and 
variant calling. Parameters were set as described in GATK’s Best 
Practices v3. GATK generated standard variant call format files (VCF  
http://www.1000genomes.org/wiki/Analysis/Variant%20Call%20Format/
vcf-variant-call-format-version-41). The VCF files were annotated using 
snpEff (snpeff.sourceforge.net) (Cingolani et al. 2012) and 
ANNOVAR(Wang et al. 2010). From this point on we focused our 
analysis only on the putative coding non-synonymous variants. 
 
Retroviral insertion sites were identified using methods derived from Complete 
Genomics based on assembling junctions. The reference genome, to which sequences 
were mapped, consisted of the GRCH37/gh19 bill augmented with two pieces of the long 
terminal repeats (LTR) common to all the retroviral vectors. These additional LTR 
sequences was added to the “end” of the genome, so that “left” and “right” sides of 
junctions could be defined. 
The ZFN-Site Search Engine with the implemented FetchGWI source code (129) 
was used for in silico identification of closely related, homologous, off-target ZFN 
  
 
44
recognition sites within two human reference genomes (GRCh37/hg19; NCBI36/hg18). 
Two bp mismatches per ZFN cassette and an allowed spacer region from 5 base pairs up 
to 16 base pairs were considered as stringency limits. 
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Chapter 3: Results 
3.1 Generation of CF-iPSCs 
Primary fibroblast cells, reported to be homozygous for the ∆F508 mutation, were 
obtained from Coriell Cell Repositories (GM04320 17yo male). Upon amplification and 
subsequent sequencing of the 500 bases surrounding the intended ZFN recognition 
sequence, we found GM04320 was actually compound heterozygous ∆I507/∆F508 
(FIGURE 3.1).  
To reprogram the fibroblast cells, they were transduced with pMXs retrovirus to 
induce ectopic expression of reprogramming factors OCT4, SOX2, KLF4, c-MYC, and 
NANOG and transferred onto MEFs for subsequent culture. Reprogramming cells were 
selected for in ESC media. By day 16 after transduction, we observed colonies that 
resembled ES colonies morphologically; there was some variation in the extent of 
resemblance to ES colonies. Live-cell staining for TRA-1-60 was used to identify 
colonies for picking. Live-staining served as a useful tool in that it identified potential 
reprogrammed colonies even before they definitively exhibited ESC-like morphology 
(FIGURE 3.2). 
Focus was placed upon two particular clones – designated iPS 17 and iPS 28 – 
based on growth properties and ESC-like morphology. Sequencing verified ∆I507/∆F508 
compound heterozygosity in the iPSCs (FIGURE 3.3a). Immunostaining for TRA-1-60, 
TRA-1-81, and Alkaline Phosphatase demonstrated that these cells expressed antigens 
characteristic of undifferentiated ESCs (FIGURE 3.3b). We also demonstrated that these 
cells can be passaged at length without significant spontaneous differentiation, as 
demonstrated in FIGURE 3.3.b via flow cytometric analysis of SSEA4 and OCT4  
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FIGURE 3.1 CF fibroblast sequencing. Primary CF fibroblast line GM04320 was 
obtained from Coriell Repositories. Sequencing revealed compound heterozygosity at the 
highlighted position (a mixture of bases T and A), indicating one allele is ∆I507 and the 
other ∆F508. 
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FIGURE 3.2 Isolating putative reprogrammed cells based on expression of TRA-1-
60. Approximately 16 days after reprogramming, putative reprogrammed colonies were 
picked based on live-staining for stem cell markers TRA-1-60 rather than morphology. 
Each of these colonies were manually picked and transferred to one well of a 12-well 
plate coated with iMEFs. Staining and imaging performed 10 days post transductions. 
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FIGURE 3.3 Characterization of iPSCs. a) Reprogrammed cells generated from 
fibroblast line GM04320 maintain ∆I507/∆F508 heterozygosity. b) iPSCs express 
markers characteristic of embryonic stem cells. Shown here is iPSC clone 17 showing 
expression of surface markers TRA-1-60 and TRA-1-81, alkaline phosphatase, and co-
expression of OCT4 and SSEA4 by flow cytometry. c) iPSCs injected into immune 
deficient mice give rise to teratomas with evidence of all three germ layers. d) iPSCs 
show normal male karyotype, suggesting reprogramming caused no gross chromosomal 
abnormalities. 
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expression, both indicative of pluripotency, in iPS17 after 33 passages. Pluripotency of 
the iPSC was additionally established via teratoma assay. When iPSCs were injected into 
immune-deficient mice, recipient mice developed tumors consisting of cell types 
characteristic of all three germ layers: mesoderm (cartilage), ectoderm (neuronal rosettes), 
and endoderm (gland) (FIGURE 3.3c). Furthermore, the CF-iPSCs still had a normal 
male karyotype (FIGURE 3.3d). 
To evaluate silencing of reprogramming transgenes as well as activation of the 
human ESC pluripotency network, the total (FIGURE 3.4a) and endogenous (FIGURE 
3.4b) expression levels of those reprogramming factors were measured by qRT-PCR and 
compared to expression levels in WA09. We did not observe significant difference 
between iPS 17 and WA09 in total and endogenous expression levels of any of the genes, 
consistent with transgene silencing. We also found little difference between iPS 17 and 
WA09 when comparing the expression profile of various genes implicated in 
maintenance of pluripotency and self-renewal of ESCs (FIGURE 3.4b).  
3.2 Gene correction of CF-iPSCs 
Correction of the CF-iPSC was accomplished via ZFN-mediated homology directed 
repair (a schema provided in FIGURE 3.5). The ZFNs were engineered to target exon 10 
of the CF locus, creating a DSB approximately 110 bp upstream of either ∆I507 or ∆F508. 
The efficacy of ZFN cutting was first assessed in a Cel-1 assay by taking advantage of 
non-homologous end joining, an error-prone mechanism for default repair of DSBs when 
no appropriate donor template is available. Briefly, cells were nucleofected to deliver 
ZFN alone. Two days later, genomic DNA was isolated and the region immediately 
surrounding the target cut site was PCR amplified. The amplicon was 
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FIGURE 3.4 Transcriptional profile of CF-iPSCs. To determine whether 
reprograming transgenes were silenced, the levels of total (transgene + endogenous; a) 
and endogenous-only (b) RNA expression were measured by qRT-PCR for each of the 
reprogramming genes, normalized to expression of GAPDH and compared to levels of 
expression in WA09 human ESCs. No significant difference in total and endogenous 
levels between the CF-iPS and WA09 is consistent with transgene silencing; the greatest 
difference observed was an approximate 3-fold increase in total C-MYC expression levels 
in iPS 17 in comparison with WA09. c) A panel of 44 human ESC-specific genes was 
analyzed in WA09 and iPS 17 by quantitative RT-PCR. Again, iPS 17 showed a similar 
gene expression pattern compared to WA09. Outliers are indicated in red with the gene 
name. Consistently, we have observed ~100-fold increase in expression of FGF5 in the 
WA09 cells relative to uncorrected iPS 17 or corrected iPS cells (Figure 3.16). Black 
lines indicate fold change of 1 and red lines indicate fold change of 3. Also included in 
the array were 5 housekeeping genes (B2M, HPRT1, RPL13A, GAPDH, and ACTB).  
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FIGURE 3.5 Schematic plan of proposed targeted CF correction. ZFNs, designed to 
induce a double strand break in exon 10 of the CF gene, are co-delivered with a donor 
molecule to serve as a template for homology directed repair of the DSB. Integration of 
the donor is selected for by puromycin selection. After successful targeted integration has 
been determined via molecular characterization, the selectable marker is excised by Cre-
recombination of the loxP sites that flank the cassette, leaving one loxP site in intron 10. 
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then denatured and renatured, treated with Surveyor nuclease, and the digested amplicon  
was resolved by gel electrophoresis. We found that 2 µg of each ZFN DNA expression 
plasmid or 1.5 ug of each ZFN RNA resulted in ~ 10% cutting, which in our limited 
experience was deemed sufficient to perform gene correction experiments (FIGURE 3.6).   
For correction, accutase dissociated CF-iPSCs were nucleofected to co-deliver the 
ZFNs (either as DNA expression plasmids or in vitro transcribed RNA) along with a 
DNA donor plasmid to serve as a template for HDR (TABLE 2). This donor contained 
1.6 kb sequences homologous to the genome flanking the ZFN cut site, which then 
includes all of exon 10 (see FIGURE 2.3). Several modifications were made to this 
homologous region. First, two silent bp substitutions were introduced in the sequences 
recognized by the ZFN-R to prevent cleavage of the donor by the ZFNs. Second, a novel 
ClaI site, which retained the exact coding sequence, was introduced approximately 20 
bases downstream of the wild-type sequences to correct ∆I507/∆F508. Lastly, a loxP 
flanked pgk-puro-TK selectable marker was inserted in the anti-sense direction 
approximately 125 bp downstream of exon 10, in intron 10 of the donor. This enabled us 
to select for those iPSCs that had integrated the donor into the genome. 
Puromycin resistant colonies (each arising from a single cell since the iPSCs were 
dissociated and subsequently plated in a diluted manner prior to selection) were initially 
screened via PCR and then sequenced to determine which resulted from targeted 
integration of the donor and to confirm correction of exon 10. Targeted integration was 
first assessed using one primer that annealed to sequences in intron 9 (but not present 
within the donor) and one primer that annealed to sequences within the selectable cassette  
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FIGURE 3.6 Efficacy of ZFN to create a DSB as assessed by Cel-1. By nucleofection 
of 2 million cells with either 2 µg of each ZFN DNA expression plasmid or 1.5 µg of 
each ZFN RNA, we are able to achieve ~10% cutting. Uncut bands are indicated by an 
arrowhead and the two bands expected from digestion of the amplicon by the Surveyor 
nuclease is indicated by arrows. Percentage of cutting is indicated below each lane. 
Genomic DNA from non-transfected cells was included in the analysis as a negative 
control 
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(primers 1 and 1’ in FIGURE 3.7a, FIGURE 3.7b). This resulted in the identification of 
21 clones from a total of two experiments (FIGURE 3.7b, TABLE 3). The 21 clones were 
further characterized by PCR amplification using primers that annealed to the selectable 
cassette and to sequences downstream of the homology region in intron 10, respectively. 
This confirmed successful insertion in seven of the 21 clones (primers 2 and 2’ in 
FIGURE 3.7a, FIGURE 3.7c, TABLE 3). Sequencing of the 1 and 1’ amplicon verified 
correction of either the ∆I507 or ∆F508 mutations as well as the presence of silent 
substitutions introduced in the ZFN-R recognition site and used to create a ClaI site 
(FIGURE 3.8). 
To determine which allele was unmodified and which was targeted, we 
distinguished the unmodified allele from targeted allele using primers that annealed to 
sequences completely outside the homology sequences in the donor (FIGURE 3.9a). 
Primers 3/3’ yield a ~1.9 kb amplicon for unmodified alleles and a ~4.5 kb amplicon for 
correctly targeted alleles. By isolation and sequencing of the specific amplicon 
corresponding to the unmodified allele (1.9 kb), we were able to determine which allele 
had been left unmodified and consequently which had been targeted (FIGURE 3.9b). For 
example, iPSC clones 17-2 and 17-21 (for which sequencing of the unmodified allele 
revealed ∆I507 genotype) were targeted at the ∆F508 allele. Sequencing of the 
unmodified allele yielded the ∆I507 mutation in three of 21 clones and the ∆F508 
mutation in the other 18 clones (summarized in TABLE 3). Thus targeted allele 
correction did not appear to occur randomly. 
As reported by Bock et al. for other human ESC and iPSC lines (130), we found that our 
uncorrected iPSC (clone 17) expressed low levels of CFTR detectable by RT- 
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FIGURE 3.7 Initial molecular analysis for targeted integration in puromycin-
resistant clones. Genomic DNA was isolated from individual puromycin-resistant clones 
and analyzed initially by PCR to determine targeted integration of the donor. a) Schema 
of the two sets of primers used: 1/1’ and 2/2’. In each set, one primer anneals to 
sequences found in CFTR but outside of sequences found within the donor molecule (1 
and 2’) and the other primer anneals to sequences found within – and specific to – the 
donor molecule (1’ and 2). b) Shown are 21 puromycin-resistant clones that yielded an 
amplicon of the expected size (1.8 kb) with primers 1/1’, two clones that did not, the 
uncorrected iPS 17, MEFs, and a no DNA negative control. c) Of the 21 clones that were 
initially identified with primers 1/1’ in panel B, 7 amplified with primer set 2/2’.  
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 TABLE 3 Summary of two experiments to correct CFTR
a total of 65 puromycin resistant colonies, conferred by integration of the donor, were 
clonally isolated, expanded, and analyzed for targeted integration 
CF locus. Indicated are the number of clones that passed each criteria and in brackets are 
the number of those that showed targeting of the 
of a total of 21 that passed, only 3 showed targetin
clones for which we had evidence by PCR, RT
were targeted at the ∆I507 allele.
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. Between two experiments, 
of the donor into the 
∆F508 allele. By our first criterion, out 
g of ∆F508. In the end, we had 4 
-PCR analysis, and sequencing. All four 
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FIGURE 3.8 Sequencing of putative targeted clones confirm targeted integration of 
donor. The donor contained two silent mutations to the right ZFN (ZFN-R) binding 
sequences (underlined in blue) of the donor: T to A and A to C (arrows). Downstream of 
the sequences to correct the ∆I507/∆F508 mutations, a ClaI restriction enzyme site 
(underlined in red) was introduced by silent mutation of one bp (arrowhead). Sequences 
of targeted clones show introduction of these three changes, further confirming targeted 
integration of the donor.  
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FIGURE 3.9 Sequencing of the unmodified to determine at which allele targeted 
integration occurred. a) Primers (3/3’) that anneal to sequences outside the donor 
homology sequences were designed to distinguish the unmodified allele from the 
modified allele. By PCR amplification with these primers, the unmodified allele would 
yield a 1.9 kb amplicon and the modified allele a 3.5 kb amplicon. b) Isolation and 
subsequent sequencing of the unmodified allele enabled us to determine for each clone in 
which allele targeted integration occurred. Indicated below the chromatograms are the 
sequences for ∆I507 and ∆F508.  
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PCR (FIGURE 3.10a). Sequencing demonstrated a mixture of expression arising from 
both the ∆I507 and ∆F508 alleles. Similarly, four (17-1, -9, -14, and -16) of the seven 
clones that passed previous PCR tests for targeted integration (FIGURE 3.7c, TABLE 3) 
yielded a single band of the same size (0.77 kb) as that seen for the original, uncorrected  
clone 17 and human ES WA09 cell lines. Sequencing of the amplicons confirmed the 
expected cDNA organization as well as expression from both unmodified and targeted 
alleles (FIGURE 3.10b and c). The other three clones (17-13, -17, and -20) also yielded 
an additional RT-PCR band of higher molecular weight, sequencing of which revealed 
abnormal cDNA organization for the targeted allele; for these clones there were two 
copies of exon 10 – either wt exon 10 together with wt exon 10 or wt exon 10 together 
with ∆I507 exon 10 (e.g. shown for 17-13 in FIGURE 3.11). We did not explore any 
further to determine how these events might have occurred, but these three clones were 
no longer considered.  Table 3 summarizes the results for each PCR and RT-PCR criteria 
from two independently performed experiments. All four successfully targeted clones 
(17-1, -9, -14, and -16) corrected the ∆I507 mutant allele to wt, leaving the ∆F508 allele 
unmodified (FIGURE 3.12). Therefore, despite gene correction, we did not accomplish 
our original goal of correcting mutant ∆F508. 
Using a probe for the pgk-puro-TK selectable cassette, Southern blot analysis was 
performed on genomic DNA isolated from the successfully targeted clones (as 
determined by having passed all criteria listed in TABLE 3; 17-1, -9, -14, -16) to 
determine whether any showed off-target integration of donor sequences (FIGURE 3.13). 
The four successfully targeted clones showed no off-target integration.  Clones 17-17 and 
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17-20, which were previously eliminated based on abnormal CFTR mRNA patterning,  
FIGURE 3.10 Correct RNA expression of CFTR in targeted clones. a) RT-PCR 
analysis of CFTR mRNA expression in the seven clones that showed targeted integration 
based on the two PCR analyses (cf. Figure 3.7 and Table 3). Also shown are CFTR 
expression for the original uncorrected iPSCs (17), iMEF, and WA09 cells. Of the seven 
clones, four (17-1, -9, -14, and -16) show an RT-PC product of the expected size (769 bp) 
while the other three (17-13, - 17, and -20) also show expression of an additional larger 
cDNA. b) Sequencing of amplified cDNA reveals a mixture of ∆I507/∆F508 from the 
original, uncorrected iPS 17 and a mixture of wt/∆F508 from those clones showing 
correct RNA expression, here clone 17-1. c) Schema of the amplicon from corrected and 
uncorrected ∆F508 alleles arising from those clones that showed the appropriate CFTR 
mRNA expression. Arrows indicate location of primers used for amplification. 
 
 
 
 
 
 
 
 
 
 
 
  
 
64
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
65
 
 
FIGURE 3.11 Incorrect mRNA expression of CFTR in some targeted clones. Both 
the lower band (blue box a for clones 17-13, 3, 4, 5, and 7)) and the upper band (blue box 
b for clones 17-13, 3, and 4) were isolated and sequenced. The sequence of the lower 
band reflected uncorrected mRNA (in these cases, ∆F508). The upper bands, on the other 
hand, reveal two copies of exon 10: either two wild-type exon 10 (17-4b) or a mixture of 
wild-type and mutant ∆I507 (17-13b and 17-3b). Arrows indicate PCR primer locations. 
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FIGURE 3.12 Sequencing of 4 correctly targeted iPSCs reveal wt/∆F508 genotype. 
Isolation of the modified allele (1 and 1’; Figure 3.7) and the unmodified allele (3 and 3’; 
Figure 3.9) reveals wt/∆F508 genotype for each of the four corrected iPSC clones 
showing appropriate RNA expression (Figure 3.10 and Table 3). 
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FIGURE 3.13 Southern blot analysis of targeted clones. Above, a schema showing the 
expected organization of the targeted allele. A 2.3 kb probe from NdeI to SpeI was used 
to detect the pgk-puro-TK selection cassette. When genomic DNA was digested with 
SpeI, the probe would hybridize with a 6.4 kb band if accurate targeting occurred. Below, 
Southern blot results indicate 4 correctly modified clones (17-4, 17-1, 17-16, and 17-9) 
and two incorrectly modified clones (17-17 and 17-20). In addition to the 6.4 hybridizing 
band, a band of approximately 3.5 kb was present for these latter two clones, both of 
which also previously showed incorrect mRNA organization. As expected, the probe did 
not hybridize with genomic DNA from the original, uncorrected iPS 17. Again, as 
expected, the 6.4 hybridizing band is also absent in two Cre-excised clones (17-9-C1 and 
17-9-C2). 
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showed additional integration of pgk-puro-TK sequences. Though no attempts were made 
to elucidate the location of the additional integration, we believe that this additional 
integration of pgk-puro-TK sequences is also likely within the targeted CFTR locus, 
consistent with the detection of additional copies of exon 10 in the CFTR cDNA from 
these clones (i.e. the additional RT-PCR bands in FIGURE 3.10). 
Because the drug selection cassette is lox-P flanked, this enabled us to quickly 
and easily remove the whole cassette by transient expression of a Cre-recombinase 
expression plasmid, which was also delivered via nucleofection. Removal of the pgk-
puro-TK cassette yielded cells that are resistant to FIAU but not to puromycin. This was 
further confirmed by PCR analysis using primers (4 and 4’) that recognized sequences 
outside the homology regions (FIGURE 3.14a and b). Using these primers yields the 
following amplicons: a 4.4 kb amplicon from the modified allele, a 1.8 kb amplicon  from 
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the modified allele after Cre-excision, and a 1.8 kb amplicon from the unmodified allele. 
The modified allele after Cre-excision and the unmodified allele can be distinguished by 
digestion with ClaI, which cleaves modified alleles twice (but not unmodified alleles). 
RT-PCR analysis of undifferentiated, corrected iPSCs confirmed appropriately sized 
CFTR cDNA, sequencing of which showed expression of CFTR mRNA from both wt 
and ∆F508 alleles (FIGURE 3.14c and d).  
We then tested whether the gene editing and/or Cre-excision methodologies adversely 
affected the pluripotency or ESC-like transcriptome profile of the iPSCs. We 
demonstrated that two of the corrected, Cre-excised iPSC clones (17-9-C1 and 17-14-C1) 
were still pluripotent, able to generate teratomas consisting of all three germ layers, and 
maintained normal karyotype (FIGURE 3.15). We also observed similar levels of total  
FIGURE 3.14 Targeted integration of donor and subsequent Cre-mediated excision 
of selection marker to correct CF-iPSCs. a) Schema of expected PCR amplicon sizes 
when using primers (4/4’) that anneal to CFTR sequences outside of the donor homology 
arms. Integration of the donor will not only introduce corrective sequences and the 
selection cassette but also a ClaI site in exon 10. Cre-mediated excision of the selection 
cassette will leave one loxP site in intron 10. b) The upper panel shows the amplicons for 
the original, uncorrected iPS 17, two corrected clones (17-9 and 17-16), and two Cre-
excised clones for each corrected clones (17-9-C1 and 17-9-C2; 17-16-C1 and 17-16-C2). 
Excision of the selection cassette is confirmed by the presence of just the 1.8 kb band, 
whereas before excision there are two bands. This is further confirmed in the lower panel, 
which shows these amplicons digested by ClaI. As indicated in the schema above, ClaI 
would cut a modified allele two times if the selection cassette is still present but only 
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once if the cassette has been excised and not at all if it the allele has not been modified. c) 
RT-PCR analysis confirming correct CFTR expression in corrected clones before and 
after Cre-excision as well as uncorrected iPS 17 and WA09. In addition to the expected 
band (0.46 kb), WA09 also shows a smaller size band. We did not examine this further. 
d) Sequencing of the CFTR RT-PCR product in panel C revealed expected mixture of wt 
and ∆F508 sequences in corrected clones before (17-9 and 17-16) and after (17-9-C1 and 
17-9-C2; and 17-16-C1 and 17-16-C2) Cre-excision. 
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FIGURE 3.15 Gene editing and Cre-excision do not alter pluripotency nor introduce 
gross chromosomal abnormalities. Above are hematoxylin and eosin staining of 
teratomas formed by two representative corrected and Cre-excised clones (iPS 17-9-C1, 
a; iPS 17-14-C1, b). Shown are examples of endoderm (gland), ectoderm (neuronal 
rosette) and mesoderm (cartilage). Normal male karyotype for each of the two clones is 
shown below. 
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and endogenous mRNA expression of reprogramming factors in Clones 17-9-C1 
(FIGURE 3.16a) and 17-14-C1 (FIGURE 3.17a) relative to expression levels in WA09 
cells, indicating continued silencing of reprogramming transgenes in these clones. We do 
note, however, an approximate 5-fold increase in total C-MYC expression in 17-9-C1 
relative to WA09; a similar increase was not seen for 17-14-C1 Additionally, we assayed 
the expression of 44 genes characteristic of human pluripotent stem cells and found 
similar expression patterns between the two corrected clones and the original, unmodified 
CF-iPS 17 (FIGURE 3.16b and FIGURE 3.17b); in addition, the transcription profiles of 
the corrected clones remained similar to that of WA09 (FIGURE 3.17c and FIGURE 
3.17c).  
To evaluate genomic integrity after reprogramming and correction, we first 
confirmed maintenance of normal karyotype for the two corrected, Cre-excised clones 
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(FIGURE 3.15). For a more detailed analysis, we then submitted genomic DNA from the 
original CF fibroblast cells, mutant CF-iPSCs (17), and two corrected and Cre-excised 
iPSC clones (17-9-C1 and 17-14-C1) for complete genome and whole exome sequencing. 
Both platforms confirmed correction of the ∆I507 (but not the ∆F508) allele in both 
corrected iPSC clones, while fibroblasts and uncorrected iPSCs had both mutations. We 
also detected in the modified allele the three silent bp substitutions introduced through 
HDR with the donor. 
Using methods derived from the Complete Genomics structural variation/junction 
detection pipeline, retroviral vector insertion sites were identified. Table 4 summarizes 
the identified sites, each found in all three iPS lines (uncorrected iPS 17, corrected 17-9-
C1 and corrected 17-14-C1): the approximate location, the orientation of insertion, and 
FIGURE 3.16 Transcriptional profile of corrected, Cre-excised Clone 17-9-C1. a) 
Total (left) and endogenous (right) expression levels of each reprogramming factor was 
normalized to expression level of GAPDH and compared to WA09. Comparison of 
expression levels of 44 genes characteristic of human ESCs in our corrected, Cre-excised 
clones vs either uncorrected Clone 17 iPSCs (b) or WA09 cells (c). The red lines indicate 
3-fold changes in gene expression and the black line indicates a 1-fold change.  
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FIGURE 3.17 Transcriptional profile of corrected, Cre
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-excised Clone 17
 
 
-14-C1 
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TABLE 4. Viral integration sites identified by complete genome and whole exome 
sequencing. Twenty-five retroviral integration sites were initially identified by methods 
derived from Complete Genomics. Indicated are the locations, orientation of integration, 
and possible genes, mRNA, or EST (as identified by UCSC genome browser) that 
overlap or are near the integration site. Looking at these specific sites, we found that 
three (highlighted in orange) are confirmable by our exome sequencing (ExomeSeq). Of 
these three, based on RefSeq, one site lies within the UTR region of an mRNA, another 
within intronic region for EPPIN-WFDC6, and the third is not found near a gene at all. 
Chr: Chromosomal location; Left: Left boundary of integration site; Right: Right 
boundary. 
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the gene affected as determined by UCSC genome browser. The general integration 
pattern was consistent with that generally seen for retroviral vectors: that is, preferential 
integration within transcriptionally active regions (note the number of integrations within 
histone markers or DNaseI hypersensitive sites). We are unable to assess what effect(s) 
retroviral integration may have on gene expression or protein function; however, the 
demonstrated silencing of the vector-expressed transgenes may suggest a decreased 
potential for the vector to transactivate neighboring genes.  
To assess whether the ZFNs had any off-target effects, we looked at the DNA 
sequences flanking identified novel non-synonymous coding variants (NSCV) for 
similarity to any permutation of the ZFN target site (TABLE 5). Requiring concordance  
between whole genome and whole exome sequencing data, we identified one NSCV in 
the CF-iPSCs, two in 17-9-C1, and seven in 17-14-C1. Importantly, none shared any 
significant homology to the ZFN recognition sequences, indicating that the NSCVs arose 
de novo rather than as a result of off-target ZFN cutting and subsequent NHEJ. 
Furthermore, in silico detection of off-target ZFN recognition sites by ZFN-Site Search 
Engine with the implemented FetchGWI source code (129), revealed no sequence within 
the genome closely related to that recognized by the ZFNs (allowing for two bp 
mismatches per ZFN, a spacer region between 5 and 16 bp, and any combination of ZFN 
dimerization). In fact, the number of NSCVs observed in the original and corrected iPSCs 
is completely consistent with that expected from reprogramming and/or long-term culture. 
Collectively, these evidence support that the CFTR ZFNs we have used are indeed 
precise, with no off-target cutting observed in coding sequences. 
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TABLE 5. Non-Synonymous Coding Variants (NSCVs) identified by whole genome 
and exome sequencing show little homology to CFTR ZFN recognition sequences. 
NSCVs, almost all of which were single base pair changes, were identified when 
comparing either corrected iPSC clones 17-9-C1 or 17-14-C1 to uncorrected iPSCs.  
Shown below the table are the CFTR sequences recognized by the ZFNs (capitalized). 
Importantly, none of the sequences flanking these NSCVs show any homology to the CF-
ZFN target site, suggesting that these NSCVs arose de novo independent of ZFN-
mediated gene editing. 
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3.3 Correction of transgene-free CF-iPSCs 
Since our initial reprogramming of CF fibroblast cells, there have been significant 
improvements made in the field, particularly towards making iPSCs that are more 
therapeutically applicable. As such, we obtained two transgene-free iPSCs (RC202 and 
RC204) that were originally generated by reprogramming homozygous ∆F508 CF 
fibroblasts with a lox-P flanked, polycistronic lentiviral vector expressing OCT4, SOX2, 
KLF4, and c-MYC that was subsequently Cre-excised (63). Using the same methodology 
employed to correct our ∆I507/∆F508 iPSCs, puromycin resistant transgene-free clones 
were first assessed by RT-PCR (FIGURE 3.18) and clones showing appropriate CFTR 
mRNA expression were then analysed by PCR to determine targeted integration. As with 
our CF-iPSCs (FIGURE 3.7a), we observed that some clones that passing the 1 and 1’ 
criterion did not also pass the 2 and 2’ criterion (data not shown). In the end, we 
identified 6 corrected clones that passed all PCR analyses and that were of genotype  
wt/∆F508 (FIGURE 3.19).  
3.4 Allele-preferred targeting 
When we mapped out our method of correcting the ∆I507/∆F508 CF-iPSCs, we 
assumed we would observe nearly equal numbers of ∆I507 and ∆F508 corrected clones, 
since there was no reason a priori to expect otherwise. Surprisingly, in two independent 
experiments (summarized in TABLE 3), we found a significant skewing towards 
correction of the ∆I507 allele over the ∆F508 allele at a 6:1 targeting ratio, respectively. 
We looked to see whether there were any differences in the sequences of the two alleles, 
paying particular attention to the 1.6 kb homology sequences present in the donor. In 
doing so, we found that there was a single bp difference in intron 9, 76 bp upstream of the  
 FIGURE 3.18 mRNA analysis of transgene
resistant colonies. To correct 
deliver ZFNs and donor. Puromycin resistant colonies were clonally isolated and first 
assessed by RT-PCR to determine appropriate mRNA expression.
were those having only a single band of 0.8 kb.
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-free iPSCs selected for puromycin 
transgene-free iPSCs, the cells were nucleofected 
 The clones of interest 
 
 
to co-
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FIGURE 3.19 Correction of transgene-free CF-iPSCs. Correction was accomplished 
using the same ZFN-mediated HDR approach applied to our ∆I507/∆F508 iPSCs. a) 
Targeted integration was assessed with the same two sets of primers used in Figure 3.7, 
wherein one primer of each set annealed CFTR sequences outside of the homology arms 
founds in the donor and the other primer of each set annealed donor-specific sequences. 
Shown are 6 clones exhibiting targeted integration of the donor in one of two transgene-
free iPSC clones (RC202 or RC204) and a ∆I507/∆F508 corrected clone (17-16). b) 
Using primers annealing CFTR sequences outside the homology arms, each sample 
exhibits two bands: the 4.4 kb band corresponding to the modified allele and the 1.8 kb 
band to the unmodified allele. c) Isolation and sequencing of each band confirms 
wt/∆F508 sequencing for each clone (a representative chromatogram is shown). 
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intended ZFN cleavage site (FIGURE 3.20a). The ∆F508 allele has a guanine, whereas 
both the ∆I507 and donor have an adenosine at this site. We speculated that if this 
increased homology between the donor and the ∆I507 allele resulted in increased 
targeting of the ∆I507 allele over the ∆F508 allele, then a change in the donor so that it 
matched the ∆F508 allele should now favor targeting of the ∆F508 allele over the ∆I507 
allele. Indeed, an A>G substitution in our donor skewed targeting from the ∆I507 allele 
in favor of ∆F508. Instead of a 6:1 ratio with Donor 1 (the “A donor”), we saw a 1:3.7 
ratio for targeting of the ∆I507 allele vs the ∆F508 allele with Donor 2 (the “G donor”) 
(FIGURE 3.20b). This single bp change resulted in a 22-fold net change. As with the 
original correction of our CF-iPSCs with Donor 1 and correction of transgene-free iPSCs, 
we observed similar patterns of targeting (ie. some of the clones passed the 1 and 1’ 
criterion did not also pass the 2 and 2’ criterion; FIGURE 21a). Using Donor 2 we were 
able to identify four clones that yielded the appropriately size amplicon in our RT-PCR 
analysis of the CFTR gene (FIGURE 3.21c), two of which showed correction of the 
∆F508 allele (FIGURE 3.22, FIGURE 3.23). 
3.5 Demonstration of restored protein expression 
Based on previous RT-PCR analysis of the CFTR gene in undifferentiated 
corrected iPSCs, we knew that mRNA expression arose from both the unmodified and 
modified alleles (FIGURE 3.10 and 3.11). We then wanted to explore whether both 
alleles would be appropriately regulated under in vitro differentiation conditions. Based 
on previous reports that treatment of human ESCs and iPSCs with Activin A induces 
differentiation into definitive endoderm, from which lung cells are derived during  
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FIGURE 3.20 Allele-preferred targeting. a) Sequencing of each allele in our 
∆I507/∆F508 fibroblast cells revealed a single base pair difference in the 1.6 kb 
homology sequences also found in the donor. This SNP is located 76 bases upstream of 
the intended ZFN cut site. b) The donor used in the experiments presented thus far had an 
A at this position (donor 1), thereby matching the ∆I507 allele more closely. In using this 
donor, the ∆I507 allele was targeted more than the ∆F508 allele (85.7% vs 14.3%; 
summarized below the schema of donor 1). In using a donor that had a G at this position 
and thus matched the ∆F508 allele more closely (donor 2), the ∆F508 allele was now 
targeted more frequently than the ∆I507 allele. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 FIGURE 3.21 Targeting of 
were assessed for targeted integration first by PCR using 1 and 1’ primers (top) and 2 and 
2’ primers (bottom). b) Those that passed both PCR criterion were then assessed for 
correct CFTR mRNA expression by RT
expression. 
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∆F508 allele with Donor 2. a) Puromycin resistant colonies 
-PCR. Four clones showed appropriate mRNA 
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FIGURE 3.22 Correction of ∆F508 with Donor 2. Using the donor matching the 
∆F508 allele, ZFN-mediated HDR was employed to correct ∆F508 in our ∆I507/∆F508 
iPSCs. a) Integration of the donor as demonstrated by using the same two primers 
previously used to initially characterize targeted integration (cf Figure3.7). Shown are 
two representative corrected clones (17-42 and 17-48) and the original, uncorrected iPS 
17. b) Using the primers that annealed CFTR sequences outside the donor homology, the 
unmodified allele was preferentially amplified, isolated and sequenced. By sequencing, 
the unmodified allele was identified as ∆I507, indicating that the ∆F508 allele had been 
corrected. 
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FIGURE 3.23 wt/∆I507 corrected clones show normal CFTR mRNA expression. RT-
PCR primers used here anneal to exon 9 and exon 13, resulting in a 0.8 kb band that is 
exhibited in all samples, both the two corrected clones and the original, uncorrected iPS 
17.  
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embryonic development (125, 131), we treated the original iPS 17 and corrected iPS 17-
9-C1 with Activin A for 3-5 days (FIGURE 3.24a, b). In doing so, we saw a moderate 
up-regulation of CFTR and SOX17 mRNAs, the latter being expressed in definitive 
endoderm. Sequencing of the RT-PCR CFTR amplicon for iPS 17-9-C1 at day 5 of 
Activin A treatment revealed approximately expression of both the mutant and corrected 
mRNAs (FIGURE 3.24b). We also explored the use of an air-liquid interface (ALI) 
culture system that was reported to give rise to tissue that resembled human airway 
epithelium (13, 132). Under these conditions for corrected clones 17-14 and 17-16, we 
also saw up-regulation of CFTR mRNA (FIGURE 3.24c); sequencing of the RT-PCR 
amplicon showed expression of both the unmodified (∆F508) and corrected (wt) mRNAs. 
Though the RNA data suggested appropriate transcription of the corrected CFTR 
allele, neither the Activin A induction of definitive endoderm differentiation nor the ALI 
culture resulted in detectable CFTR protein expression. By adopting a step-wise 
differentiation of definitive endoderm into NKX2.1-expressing lung and thyroid 
progenitors as described by Green et al. and Longmire et al. (summarized in FIGURE 
3.25a) (79, 127), we were able to differentiate both uncorrected (17) and corrected, Cre- 
excised (17-16-C1) iPSC clones, as well as WA09 cells, into populations of which 79-
95% expressed both CXCR4 and C-KIT, both definitive endodermal markers, after 4 
days of differentiation (FIGURE 3.25b).  
After subsequent anteriorization and ventralization to derive anterior foregut 
endodermal cell fates  (day 19 in FIGURE 3.25a), we observed increased expression of 
pan-endodermal marker FOXA2; thyroid marker PAX8; and lung markers NKX2.1, SOX9 
(of which coexpression with NKX2.1 indicate distal lung bud epithelium (133), and P63  
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FIGURE 3.24 Corrected CFTR mRNA expression by iPSC-derived cells. a) mRNA 
expression pattern of uncorrected iPS 17 for CFTR and SOX17 over 3 days of Activin-A 
induction of corrected. b) Gene expression pattern of corrected, Cre-excised iPSC Clone 
17-9-C1 over 5 days of Activin-A induction show similar upregulation of CFTR and 
SOX17. CFTR RT-PCR amplicon at day 5 (blue box) was isolated and sequenced 
confirming co-expression of ∆F508 and wt alleles. c) mRNA expression pattern of CFTR 
in uncorrected, undifferentiated (17 iPS) and uncorrected, differentiated (17 ALI) cells as 
well as two corrected and differentiated cells (17-14 ALI and 17-16 ALI). Differentiation 
was accomplished by maintaining cells in air-liquid interface culture conditions, whereby 
clumps of iPSCs were cultured within semi-permeable inserts with ESC media both 
outside and inside the insert (liquid-liquid conditions) for four days then in differentiation 
media under liquid-liquid conditions. After 5 days of liquid-liquid differentiation media 
conditions, the cells were maintained under air-liquid conditions with differentiation 
media only in the outside the insert. Sequencing of the uncorrected, differentiated and 
one of the corrected, differentiated samples reveal ∆I507/∆F508 and wt/∆F508 
sequencing, respectively. GAPDH was used as a loading control. 
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FIGURE 3.25 Differentiation of iPSCs into NKX2.1-expressing anterior foregut 
progenitors to lung and thyroid lineages. a) Summary of the differentiation protocol 
adapted from Green et al. (2011) and Longmire et al. (2012). Embryoid bodies are 
formed (Day 0) and differentiated into definitive endoderm, which gives rise to both 
anterior and posterior foregut, by induction of TGFβ signaling via Activin A treatment 
(Days 1-4). Then, after a brief inhibition of TGFβ and BMP signaling pathways by SB-
431542 and Noggin, respectively, the cells are treated for 11-13 days with a cocktail to 
ventralize into anterior foregut progenitors that express NKX2.1. b) At Day 4 of 
differentiation, some of the cells are analyzed by flow cytometry for expression of 
definitive endodermal markers CXCR4 and C-KIT. If the population is ≥ 70% double-
positive, we proceed with the anteriorization step. c) Expression profile of differentiated 
cells after 19 days indicate differentiation towards early lung and thyroid endodermal 
lineages. 
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(basal cells) (FIGURE 3.26). Significantly, CFTR expression increased 10- to 
100-fold (depending on the experiment) when compared to undifferentiated cells, though 
levels of expression in day 19 differentiated cells were still low compared to positive 
controls (fetal lung, fetal thyroid, and – in the comparison of CFTR gene expression – 
Calu3 cells). Sequencing of the CFTR RNA produced by the day 19 differentiated 
population confirmed the expected CFTR mRNA organization and sequence (i.e. Clone 
17 being ∆I507/∆F508 and Clone 17-16-C1 being wt/∆F508 while both WA09 and 
CFTR-expressing Calu-3 cells expressed wt RNA; FIGURE 3.27).  
Importantly, we were now also able to detect CFTR protein by western blot in the 
day 19 cultures (FIGURE 3.28). In CFTR-expressing Calu-3 cells and differentiated 
WA09, we detected a protein band of ~170 kDa (arrow; - columns) that is consistent with 
a mature CFTR protein. The mature CFTR protein is sensitive to deglycosylation when 
treated with an N-glycosydase F (arrowhead; + columns), as evident by a reduction in 
molecular weight to ~140 kDa. We detected only a slight amount of the ~140 kDa protein 
and none of the 170 kDa protein in cells derived from the uncorrected iPSCs (Clone 17). 
Significantly, correction of the Clone 17 ∆I507/∆F508 genotype to wt/∆F508 in the 17-
16-C1 iPSCs now resulted in restored expression of the 170 kDa CFTR protein. As 
expected this mature glycoform was also glycosylase sensitive. 
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Figure 3.26 Expression profile of differentiated cells after 19 days indicate 
differentiation towards early lung and thyroid endodermal lineages. RNA was 
isolated from day 19 differentiated cells derived from uncorrected iPS Clone 17, 
corrected and cre-excised Clone 17-16-C1, or WA09. Expression levels measured by 
qRT-PCR indicate upregulation of pan-endodermal marker FOXA2, Thyroid marker 
PAX8, and several lung markers (CFTR, NKX2.1, SOX9, P63, and FOXP2) as well as 
downregulation of pluripotency marker OCT4, indicating differentiation towards early 
anterior foregut lineages. As a positive control, RNA extracts from fetal lung, fetal 
thyroid, and Calu-3 cells were included where applicable. Note that y-axis is on a log 
scale 
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FIGURE 3.27 Differentiated cells express CFTR RNA with expected sequence. 
Sequencing of CFTR mRNA isolated from CFTR-expressing Calu-3 cells and from 
differentiated cells derived from WA09 show expected wild-type sequence, whereas 
when isolated from differentiated uncorrected iPSCs (Clone 17) both ∆I507 and ∆F508 
deletions are observed. Importantly, cells differentiated from corrected, Cre-excised iPS 
(Clone 17-16-C1) produce mRNA with one wt and one ∆F508 allele, corresponding to 
carrier state.  
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FIGURE 3.28 Differentiated corrected iPSCs express mature CFTR. As expected, 
immunoblotting of wild-type Calu-3 cells and those differentiated from WA09 show a 
predominance of the fully-glycosylated, mature form of CFTR of ~170 kDa (arrow). This 
mature isoform is sensitive to deglycosylation by PNGase F, an N-glycosidase, (+) 
resulting in a reduction of molecular weight to ~140 kDa corresponding to an immature 
CFTR (arrowhead). Uncorrected iPS (17), on the other hand, does not generate mature 
CFTR protein but show low level of the immature isoform, which is quickly degraded 
before reaching structural maturity. However, correction of one allele, as in cells derived 
from 17-16-C1, restores the fully-glycosylated, mature form that shows similar sensitivity 
to PNGaseF as did Calu-3 and cells derived from WA09. Calnexin was used as a loading 
control. 
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Chapter 4: Discussion 
The ability to reprogram pluripotent stem cells directly from patient skin or other 
somatic cells and to edit the genome in a site-specific manner in these induced pluripotent 
stem cells, has opened up an avenue for treatment of monogenic diseases like Cystic 
Fibrosis. CF is an autosomal recessive disease for which current treatments provide only 
short-term alleviation of symptoms and attempts at gene therapy have failed (largely due 
to inefficacy of targeting appropriate cell types and issues with immune responses against 
repeated delivery of the virus). We thus sought to apply these two novel technologies to 
CF as groundwork for alternative cellular and gene therapy – the goal being to provide an 
autologous, long-term treatment that not only addresses symptoms but also is curative in 
essence. We have shown that zinc finger nuclease-mediated homologous directed repair 
can be used to correct two distinct CFTR mutations (∆I507 and ∆F508) in iPSCs; for 
these studies we utilized either iPSCs derived by retroviral-mediated integration of the 
reprogramming factors or iPSCs generated in a transgene-free method by another 
laboratory. Furthermore, we have demonstrated that such correction was made with no 
apparent off-target effects in exon sequences as indicated by complete genome and whole 
exome sequencing, as well as bioinformatic analysis of potential off-target sites. 
Significantly, we prove that differentiated cells derived from the corrected iPSCs produce 
the fully glycosylated, mature form of CFTR.  
4.1 Generation of CF-iPSCs 
When we first began to generate iPSCs, we relied on viral delivery of the 
reprogramming factors originally used by Yamanaka's and Daley’s groups (45, 46). We 
initially attempted to use lentivirus to deliver the Thomson reprogramming factors (134), 
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but succeeded only with retrovirus expressing the 4 Yamanaka factors plus NANOG. As 
reported by others, we found that the key to reprogramming was having high titers of the 
reprogramming vectors. Given that reprogramming is an inefficient process, it is crucial 
to maximize the number of starting cells receiving all reprogramming factors. 
Furthermore, Yamanaka and colleagues showed that iPS generated using retrovirus had 
integrated three to six copies of each factor, suggesting that a certain combination and/or 
level of induction is required for full reprogramming (45). Thus, to achieve high titers of 
our retrovirus, we adapted Park and Daley's protocol for VSV-G pseudotyped retroviral 
vectors, which allowed us to concentrate the virus production by ultracentrifugation and 
thus transduce at a high multiplicity of infection (120).  
Upon delivery of the factors and selection for reprogramming cells, isolation of 
those cells became crucial in creating clonal iPSC colonies. In their detailing of the 
reprogramming process, Lowry et al. described the emergence of two waves of colonies. 
The first wave was found to be unexpandable (56). Significantly, they showed that this 
first wave consisted of colonies transduced only with OCT4 and C-MYC retroviruses. It 
was from the second wave of colonies, which they found to be TRA1-81 positive, that 
they isolated fully reprogrammed colonies. We also observed two waves of colonies 
arising from our experiments. In isolating our iPSCs, we initially relied on morphology 
alone, looking for the morphologies as described by Lowry et al. We observed many 
colonies that fit the human ESC colony morphology, but the first wave of colonies did 
not expand.  Furthermore, we found that, when we used live cell staining for antigen 
TRA-1-60 as another criteria, morphology and TRA-1-60 positivity did not always 
coincide (FIGURE 3.2). Many of these colonies that did not initially resemble ESC 
  
 
101
colonies but expressed TRA-1-60 began to take on a morphology indistinguishable from 
ESCs as they were isolated and further passaged. Thus, we found live-cell staining for 
TRA-1-60 to be a more reliable indicator of reprogramming. 
4.2 ZFN-mediated correction of CF-iPSCs 
  Having generated CF-specific iPSCs that were ∆I507/∆F508 compound 
heterozygous, our objective was to then generate a patient-specific iPSC line for CF that 
was corrected for the disease-conferring mutation with as little change to the underlying 
cellular genome as possible. While the method we used for reprogramming resulted in 
multiple integrations (thus compromising the integrity of the cell's genome) this can be 
circumvented for future clinical applications with Cre-excisable polycistronic or non-
integrating reprogramming vectors, as previously discussed. When it came to correcting 
the CF mutation, we chose site-specific approach correction of the endogenous mutation 
rather than integration of the wt CFTR cDNA in a safe harbor or random integration site; 
our objective was that regulation of the corrected CFTR gene would still be under the 
control of endogenous CFTR gene regulatory elements.  To facilitate site-specific gene 
targeting, we utilized ZFNs bioengineered to create a DSB in exon 10 of the CF locus, 
upstream of the ∆I507/∆F508 mutations. The ZFNs were obtained through a 
collaboration with Sangamo Biosciences, who not only bioengineered the ZFNs but 
provided much insight and guidance on optimizing the delivery of the ZFNs as well as on 
construction of a donor suitable for our purpose.  
There were several considerations in the design and construction of the donor. 
The first thing we considered was the length of the homology arms. While 5 to 10 kb of 
total homology is typically recommended for traditional HR in mouse or human (135), 
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zinc finger nuclease-mediated HR require significantly shorter homology sequences (on 
the order of 1-1.5 kb total). For example, Moehle et al. demonstrated that both 1 kb and 
7.7 kb insertions, each flanked by 750 kb homology arms, were incorporated by ZFN-
mediated HDR at an efficiency of about 5% (106). We, thus, decided to construct our 
donor similarly with approximately 1.6 kb of total homology. This would, based on the 
location of the DSB, encompass all of exon 10 with enough room on each end to include 
splice signal sequences and flanking intron sequences. Additionally, because the 
homology arms would also include the ZFN recognition sequence, we introduced two 
single base pair mutations that would alter the sequence recognized by the right ZFN 
without altering the encoded amino acid sequence.    
Though Soldner et al. have demonstrated the ability to integrate genes in iPSCs 
without the use of drug selection (53), we opted to take a drug-selection based strategy to 
afford us the ability to quickly assess and select for integration events. We found that 
puromycin, more so than neomycin, provided swift and efficient selection to minimize 
the chances of growth of cells without integration. By utilizing a positive/negative 
selectable marker conferring puromycin resistance and thymidine kinase (TK) sensitivity, 
we were able to distinguish integration events by positive selection of puromycin 
resistance and, later, Cre-excision events by FIAU resistance. In addition, we wanted our 
selection marker to be excisable and so opted for one that was flanked by loxP sites, 
similar to the excisable selection marker utilized in correction of sickle cell anemia (114). 
By Cre-mediated recombination, the selection marker could be excised leaving just one 
loxP site of 34 bases still integrated. For future adaptation of our methods, if a selection 
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marker is used, we suggest that they be flanked with piggyBac transposon sequences, 
which allows for excision without leaving any residual sequences. 
In order to keep the homology arms of almost equal lengths on both sides of the 
ZFN target site, we initially put the selection marker in intron 9, approximately 100 bases 
upstream of exon 10 (FIGURE 4.1). In our first few experiments using this construct to 
correct the ∆I507/∆F508 iPS, the donor was and ZFNs were delivered by electroporation 
using protocols not yet optimized. We were able to isolate a sufficient number of 
puromycin-resistant colonies, a small number of which showed evidence of targeted 
integration by PCR. However, analysis of the sequence for these putative targeted 
integrations revealed no correction of either the ∆I507 or ∆F508 alleles. This suggests 
that HR did not extend far enough to include the corrective sequences from the donor to 
repair the ∆I507 or ∆F508 mutations. Due to the low number of puromycin-resistant 
clones from samples nucleofected with donor alone, it is unlikely that these puromycin-
resistant yet not corrected clones resulted from random integration events; however, we 
did not investigate these clones any further and thus cannot conclusively exclude this 
possibility.  
Our collaborator, Dr. Michael Holmes from Sangamo Biosciences, then suggested 
placing the selection cassette in intron 10. While we were not able to preserve the equal 
size of homology arms, this would place any changes in the donor relative to the 
endogenous CFTR sequences on one side of the DSB and, importantly, require any HR 
event that integrated the selection cassette to also include the corrective sequences. It was 
with this donor, in which the selection cassette was placed in intron 10, that we were able 
to obtain colonies with targeted correction.  
 FIGURE 4.1 Donor with selectable cassette in intron 9.
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Another consideration was whether to correct before or after reprogramming. 
Because 1) correction would require expansion both before and after Cre-excision and 2) 
reprogrammed cells can be passaged for a long time without senescence, we opted to 
reprogram the cells first and then correct them. Another benefit of this approach is that 
we could generate banks of both uncorrected and corrected iPSCs that were clones of one 
another except for the changes introduced during the correction. Had we corrected first, it 
would be highly unlikely that we would have uncorrected and corrected reprogrammed 
cells that had the same reprogramming profile (i.e. number and location of insertions of 
reprogramming factors). There are, however, cases in which correction before 
reprogramming would be beneficial. Such is the case with Fanconi anaemia, where cells 
show genomic instability and are predisposed to apoptosis (52). In this case, investigators 
found it beneficial to correct before or at the same time as reprogramming.  
4.3 Evidence of allele-preferred targeting 
Sequencing of colonies that showed targeted integration of the donor with the 
selection cassette in intron 10 (Donor 1) revealed significant preferential targeting of one 
allele over the other (6:1 targeting of ∆I507 over ∆F508; FIGURE 3.20). Given that the 
number of changes in the donor relative to the two endogenous alleles was the same (i.e. 
insertion of 3 bp), we anticipated nearly equal targeting of both alleles. Demonstrated 
CFTR mRNA expression arising from both the ∆I507 and ∆F508 alleles in the targeted 
Clone 17 iPSCs suggested that this allele preferential targeting was not due to different 
transcriptional activity (e.g., if ∆I507 had been transcribed but ∆F508 silent). Further 
investigation into the sequences of each allele, specifically those sequences that were 
included in the donor, revealed that there was, in fact, a single base pair difference 76 bp 
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upstream of exon 10 (this same SNP was also found in the originating fibroblast cells and 
is a documented SNP). Where the endogenous ∆I507 allele had an adenosine, the ∆F508 
allele had a guanine; the original donor we had constructed had an adenosine, thus 
matching the ∆I507 allele at this position. Changing the donor such that it matched the 
∆F508 allele at this position resulted in a reversal of preference with 1:3.7 (∆I507:∆F508) 
showing targeting (Donor 2, FIGURE 3.20. Though surprising that a single base pair 
difference could have such drastic effects, our finding corroborates past experiments by 
Waldman and Liskay in 1988 (109) and later by Elliot et al. (110); both groups found that 
critical to efficiency of HR is the amount of uninterrupted homology. Collectively, these 
findings would suggest, then, that a break in contiguous homology introduced by a SNP 
76 bases upstream of exon 10 (87 bp from the spacer region) would not provide a 
sufficient stretch of uninterrupted homology for efficient repair of a DSB (FIGURE 4.2). 
These findings underscore the need to closely inspect and match the sequences in the 
donor to those present in the targeted cell line(s), subtle changes could account for low 
targeting efficiencies. Additionally, this ability to preferentially target a specific allele 
might be advantageous in cases where targeting of one allele vs the other is essential in 
restoring the gene, as in dominant diseases like Huntington’s disease or myotonic 
distrophy. 
4.4 Targeting and correction of one vs two alleles 
In attempting to correct either the compound heterozygous CF-iPSCs or the 
homozygous ∆F508 transgene-free iPSCs, we achieved targeting and correction of just 
one allele. There are several factors that we believe would be necessary to achieve 
biallelic correction (though, again, not necessary for a recessive disease like Cystic 
 FIGURE 4.2 Mechanism for preferential targeting.
is a resection of the 5’ ends of each cut strand. Then, in strand displacement annealing the 
cut strand invades the template and is repaired in 5’ to 3’ direction using the antisence 
donor strand as a template. If a SNP 
upstream of the DSB in the genome but beyond the portions resectioned, this SNP can 
inhibit proper invasion and, thus, strand displacement annealing. 
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exists between the donor and the template just 
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Fibrosis). First we would have to increase the efficiency of cleaving both alleles by the 
ZFNs, since this is a requisite event for targeting. Sequencing of the unmodified alleles in 
our CF-iPS cells targeted with Donor 1 (FIGURE 3.20) revealed that that only 1 out of 
the 21 clones sequenced showed evidence of cutting as evidenced by introduced 
mutations at the cut site by NHEJ (data not shown). This suggests that the ZFNs used in 
our experiments rarely cut both alleles. Second, to achieve biallelic targeting we would 
also have to select a donor(s) that matched each of the targeted alleles. In the case of the 
homozygous ∆F508 cells (sequencing of which showed that both alleles had a G at the 
position in intron 9), Donor 2 should be used for optimal targeting. For targeting of our 
compound heterozygous CF-iPSCs, the use of both donors (the Donor 1 for ∆I507 and 
the Donor 2 for ∆F508) would increase the possibility of sucessful targeting of both 
alleles. Finally, to select for biallelic targeting, we would suggest the use of a double 
selection method, one specific for each allele. For example, one of the donors would 
confer puromycin resistance while the other confers neomycin resistance. Selection of 
puromycin and neomycin resistant colonies would then enrich for those with targeted 
integration of both donors. 
4.5 Demonstration of restored CFTR protein expression by targeted differentiation 
of corrected iPSCs 
Since CF-related complications in the lung account for 90% of CF morbidity and 
mortality, we explored differentiation of our iPSCs into lung cells with the goal of 
demonstrating correction-mediated restoration of expression of the CFTR protein. 
Fortunately, there has been much headway in elucidating the pathways involved in lung 
organogenesis and how to translate this into a differentiation protocol for human ESCs. 
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Building upon these studies, we have been able to differentiate several pluripotent stem 
cells and demonstrate CFTR expression.  
Though there is still some question of the specific lung cell type(s) that express 
CFTR, we initially assumed we would have to generate fully differentiated, mature cells 
(like ciliated cells) to observe CFTR protein. When we finally began differentiation 
experiments, there were reports of differentiation of pluripotent stem cells into definitive 
endoderm, the precursor to the anterior (lung and thyroid) and posterior (intestine, liver, 
pancreas) foregut, in a way that attempts to recapitulate normal embryonic development: 
by inducing Nodal/Activin signaling, Activin A treatment can effectively generate 
definitive endoderm from mouse and human ESCs (125, 131). There were also two 
reports of the generation of respiratory epithelia-like tissue from mouse and human ESCs 
(13, 132). These latter reports relied on spontaneous differentiation guided by culture 
conditions that mimic the air-liquid interface (ALI) of the lung. When we tried to 
reproduce both the protocols for definitive endoderm and for lung epithelial tissue, we 
did observe upregulation of CFTR gene expression by qPCR (FIGURE 3.24), sequencing 
of which revealed appropriate transcriptional regulation of both the corrected and 
unmodified alleles. We also observed, in the Activin A experiments, expression of Sox17, 
a gene expressed in definitive endoderm. Unfortunately, though we were able to detect 
CFTR mRNA, we were unable to detect CFTR protein. 
Because these attempts by Coroux et al. and Van Haute et al. rely on spontaneous 
differentiation, it is questionable whether the tissue generated is purely lung tissue. 
Furthermore, it is still unclear whether these reports are reproducible. We, thus, put our 
efforts into more step-wise differentiation approaches like that employed in the derivation 
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of definitive endoderm. The belief and hope is that by taking an approach that attempts to 
mimic the signaling pathways that direct lung organogenesis, we can then begin to 
establish protocols that will efficiently and reproducibly generate the specific cell types in 
which we are interested, including both CFTR-expressing cells as well as progenitors to 
such cells. Two groups have paved the way for such step-wise differentiation of 
definitive endoderm into anterior foregut and subsequently early lung progenitors (79, 
80). Taking their cues from normal development, both groups emphasized the need to 
generate, from definitive endoderm, the primordial progenitors to the anterior foregut. 
This stage, which is marked by NKX2.1 expression, requires anteriorization due to 
inhibition of BMP and TGFβ signaling and then ventralization. Longmire et al. went 
further and showed that murine ESC-derived Nkx2.1+ cells were capable of further 
differentiation into more mature lung and thyroid lineages as determined by detection of 
lung- and thyroid-specific mRNAs. In collaboration with the Kotton group, we assessed 
whether their step-wise differentiation of murine ESC-derived Nkx2.1-expressing cells 
could be translated for differentiation of human ESCs and iPSCs, with the hopes of 
generating CFTR-expressing cells, as well as other lung and thyroid lineages. 
We began to observe significant upregulation of CFTR mRNA (relative to 
positive controls) upon anteriorization and ventralization of definitive endoderm 
(FIGURE 3.27). We, thus, explored whether we could detect even low levels of CFTR 
protein at this point, and we were able to detect CFTR protein after 19 days of 
differentiation (FIGURE 3.28). Notably, when derived from uncorrected iPSCs (17), only 
low levels of the immature, core-glycosylated form of CFTR is observed; however, when 
derived from corrected, Cre-excised iPSCs (17-16-C1), both the core- and fully-
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glycosylated forms are observed. Sensitivity to deglycosylation by N-glycosidase F of the 
protein detected from the 17-16-C1 derived cells, further confirms that the upper band is 
the fully glycosylated, mature form of CFTR. Patterns observed from the 17-16-C1 
derived cells are indistinguishable from that observed from similarly differentiated WA09 
cells and from CFTR-expressing Calu-3 cells. It must be noted that mRNA expression 
profile of the differentiated cells suggest that we have not generated just lung and thyroid 
progenitor(s) but rather a heterogenous population. We thus cannot make any conclusion 
about whether these are lung CFTR-expressing cells. Nonetheless, these results still 
conclusively indicate that these CF-iPSCs that were corrected by ZFN-mediate HDR can 
differentiate into cells that produce the mature, fully glycosylated CFTR. 
Recently, two groups have used ZFNs to restore or induce CFTR gene expression. 
Lee et al. used ZFNs to perform site-specific correction of the ∆F508 mutation in 
bronchial epithelial cells (136). However, they failed to demonstrate restored CFTR 
protein expression. Furthermore, they did not clonally isolate the corrected cells. 
Ramalingam et al. reported integration of the CFTR transcription unit into the CCR5 safe 
harbor locus in wild-type iPSCs with constitutive CFTR expression already in 
undifferentiated iPSCs (137). We report here the first documentation of site-specific 
correction of the CFTR gene in CF-specific iPSCs, as demonstrated at both the genetic 
and protein level. This is, additionally, the first demonstration of allele-preferred 
targeting in human cells, an observation that may help improve targeting efficiencies and 
assist in correcting dominant mutations. 
4.6 Future direction 
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 As already noted above, there are areas in which improvements need to be made 
before our demonstration of site-specific correction of CF-iPSCs is clinically applicable 
(eg. the effects of the reprogramming process and prolonged culture of iPSCs on its 
genomic and epigenomic stability; improved efficacy of site-specific, DSB-induced 
homologous recombination; and derivation of pure and functional populations of lung 
epithelial cells from pluripotent stem cells). Discussion of future work and direction, then, 
will focus primarily on 1) assessing appropriate cellular localization of CFTR and 
restored protein function and 2) how these cells can be used for cellular therapy of CF. 
 We have shown that the genetic correction made to the CF-specific iPSCs is 
appropriately translated as we are able to detect CFTR protein by western blot. As the 
absence of CFTR in ∆I507 and ∆F508 patients is due to misfolding of the protein, arrest 
of protein maturation, and subsequent degradation of the immature protein, it follows that 
genetic correction of the mutation that results in expression of mature CFTR protein 
would result in proper trafficking of the protein. Immunostaining of CFTR at the apical 
surface of CFTR-expressing cells is sufficient to demonstrate appropriate localization of 
the restored CFTR protein. To unequivocally prove apical expression of the protein, we 
would need to generate a polarized culture. 
If the corrected CFTR is appropriately trafficked to the apical membrane, we 
should be able to detect restored chloride transport function by electrophysiological 
assays, such as patch-clamp or Using chamber. As both techniques will require quite a bit 
of expertise that we do not have, we have been actively considering another option: 
chloride flux assays. Using fluorescent probes sensitive to iodide, which is also CFTR 
permeable, intracellular fluorescence is used as an indicator of CFTR activity upon 
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activation with forskolin and inhibition upon treatment with CFTR-specific inhibitor 
CFTRinh-172 (138-140). Unlike Patch-clamp, this assay seems to be more straightforward. 
Furthermore, unlike Ussing chamber, the assay can be performed on dissociated cells, 
thus polarity is not a requirement. If sensitivity is an issue, we might consider radioactive 
tracers, which are more sensitive to small fluxes.  
With proof that functional CFTR-expressing cells can be generated from the 
iPSCs, we are one step closer to making cellular therapy a viable option for treatment of 
CF. Transplantation of CFTR-expressing cells derived from the corrected iPSCs would 
provide immediate treatment for CF. However, because these are terminally 
differentiated cells and the airway epithelium has a quick turnover rate (1), co-delivery of 
stem progenitors to those CFTR-expressing cells could treat provide long-term treatment 
of the disease. Unfortunately, as aforementioned, neither the CFTR-expressing cells nor 
the progenitor(s) to those cells have been unequivocally identified. Considerations for 
means of delivering the cells will also not be trivial. For example, the CF lung will 
already exhibit damage and viscous mucous, which may inhibit engraftment of 
transplanted cells (as it inhibits efficient delivery of viral gene therapy agents). 
As an alternative, many labs are exploring the possibility of using a lung scaffold 
to help direct differentiation of pluripotent and multipotent cells (141-143). For example, 
Niklason and collegues decellularized a rat lung resulting in an extracellular matrix 
scaffold that maintained the branching structure of the lung (144). By seeding the 
decellularized lung with pulmonary epithelium and vascular endothelium, they 
demonstrated the cells were capable of repopulating the respiratory compartments and, 
notably, the engineered lung was capable of gas exchange when transplanted into rats in 
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vivo.  These and similar works have sparked interest aimed at determining whether these 
decellularized lung scaffolds that can be populated by the corrected iPSCs or, more likely, 
early lung progenitors (NKX2.1+) cells derived from corrected iPSCs to generate a 
functional lung for transplantation. 
As quickly as advances in reprogramming (to make iPSCs more clinically safe) 
are being made, the limiting step for clinical application of these cells, I believe, lies with 
directed differentiation of target cells (ie. the affected cell types or progenitors to those 
cells). Nonetheless, even in the time it has taken to write this dissertation, we have 
learned that there has been progress made in further differentiating iPSCs into lung cells 
and the use of these cells in recellularization of lung scaffolds. Furthermore the Japanese 
Ministry of Health has just approved a clinical study into treatment of age-related 
macular degeneration using iPSC-derived retinal pigmented epithelium (145) and the US 
FDA has approved a phase I clinical trial on the safety and tolerability of iPS-derived 
retinal pigmented epithelium in patients with Stargardt’s Macular Dystrophy (clinical 
trial identifier NCT01345006). Though there are concerns about the readiness of iPSCs 
and iPSC-derived cells for human use, these pilot studies is just one indication of the 
speed at which research, and even clinical translation, in this promising area of 
regenerative medicine is progressing. 
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